Interferon Beta-1α ring prophylaxis to reduce household transmission of SARS-CoV-2: the Containing Coronavirus Disease-19 randomized clinical trial

3 Authors

- 4 José A. Castro-Rodriguez, PhD
- 5 Pontifical Catholic University of Chile
- 6 Eleanor N. Fish, PhD
- 7 University of Toronto
- 8 Tobi Kollmann, PhD
- 9 Telethon Kids Institute
- 10 Carolina Iturriaga, RN
- 11 Pontifical Catholic University of Chile
- 12 Yuliya Karpievitch, PhD
- 13 Telethon Kids Institute
- 14 Casey Shannon, BSc
- 15 Prevention of Organ Failure (PROOF) Centre of Excellence
- 16 Virginia Chen, BSc
- 17 Prevention of Organ Failure (PROOF) Centre of Excellence
- 18 Robert Balshaw, PhD
- 19 Centre for Healthcare Innovation, University of Manitoba
- 20 Samuel T. Montgomery, PhD
- 21 Telethon Kids Institute
- 22 Joseph Ho, MSc
- 23 Telethon Kids Institute
- 24 Rym Ben Othman, PhD
- 25 Telethon Kids Institute
- 26 Radhouana Aniba, PhD
- 27 Telethon Kids Institute
- 28 Francisca Gidi-Yunge, DDS
- 29 Pontifical Catholic University of Chile
- 30 Lucy Hartnell, MSc
- 31 Telethon Kids Institute
- 32 Guillermo Pérez-Mateluna, Biotech
- 33 Pontifical Catholic University of Chile
- 34 Marcela Urzúa, RN
- 35 Pontifical Catholic University of Chile
- 36 Scott Tebbutt, PhD
- 37 Prevention of Organ Failure (PROOF) Centre of Excellence
- 38 Diego García-Huidobro, PhD

39 Pontifical Catholic University of Chile

40 Cecilia Perret, MD

41 Pontifical Catholic University of Chile

42 Arturo Borzutzky, MD

43 Pontifical Catholic University of Chile

44 Stephen M. Stick, PhD

45 46 Telethon Kids Institute

47 **Corresponding author:** Professor Stephen Stick

48 <u>stephen.stick@health.wa.gov.au</u>

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

Abstract (351 words) Importance: Evidence suggests that early, robust type 1 interferon responses to SARS-CoV-2 are critical determinants for COVID-19 disease outcomes, accelerating viral clearance and limiting viral shedding. **Objective:** We undertook a ring prophylaxis study to determine whether pegylated IFN β -1 α could reduce SARS-CoV-2 household transmission. **Design:** A cluster randomized clinical trial of pegylated IFN β -1 α conducted in Santiago, Chile. Recruitment was conducted between December 4th 2020, and 31st May 2021, with the last follow-up completed June 29th 2021. **Setting:** The study was conducted across 341 households in the metropolitan area of Santiago, Chile. Participants: Index cases were identified from databases of those with confirmed SARS-CoV-2 from COVID-19 clinics and emergency room visits in Santiago, Chile. 5,154 index cases were assessed for eligibility, 1,372 index cases were invited to participate, and 341 index cases and their household contacts (n = 831) were enrolled in the study. Intervention: Households were cluster randomized to receive 125μg subcutaneous pegylated IFNβ-1α (n = 172 households, 607 participants), or standard care (n = 169 households, 565 participants). Main Outcome(s) and Measure(s): Frequentist and Bayesian analyses were undertaken to determine the effects of treatment on (i) reducing viral shedding in index cases and (ii) reducing viral transmission to treatment-eligible household contacts. Four secondary outcomes were assessed including duration of viral shedding, effects on viral transmission and seroconversion, incidence of hospitalization, and incidence and severity of reported adverse events. A post-hoc 'at risk population' was defined as households where the index case was positive at the start of the study and there was at least one treatment eligible contact in a household who tested negative for SARS-CoV-2.

Results: In total, 1172 participants in 341 households underwent randomization, with 607 assigned to receive IFN β -1 α and 565 to standard care. Based on intention to treat and per protocol analyses, IFN β -1 α treatment was ineffective. However, in the 'at risk' population, the relative risk of infection was reduced by 23% in treated individuals and that there was a 95% probability that IFN β -1 α reduced household transmission

Conclusions and Relevance: Ring prophylaxis with IFN β -1 α reduces the probability of SARS-CoV-2 transmission within a household.

Trial Registration: Clinicaltrials.gov identifier: NCT04552379

Introduction (Words 3284)

The SARS-CoV-2 pandemic has claimed over six million lives. Despite the rapid development and deployment of vaccines in many countries, the number of new cases worldwide still exceeds 500,000 daily (https://covid19.who.int). With each wave of the pandemic, health systems have been challenged and the likelihood of emergence of mutant strains of the virus remains. Mutated strains may be more transmissible ^{1,2}, cause more severe disease than the original pandemic strain of SARS-CoV-2 ³ and have the potential to evade available vaccines ^{4,5}. Whilst widespread vaccination has had success limiting the trajectory of the pandemic, the emergence of the omicron variants demonstrated that even with mutations that appear to cause less severe disease ⁶, high transmission despite immunization could still result in significant pressures on health services ⁷.

The solution to halting any pandemic is ending community transmission. During the current pandemic, measures such as healthy hygiene, self-isolation when sick, physical-distancing and use of facemasks have all been effective ⁸. Moreover, expedited public health responses such as extensive contact-tracing, testing for infection and community lockdowns have all been effective methods to curb transmission ⁹. International and local border closures plus strict quarantine measures have reduced community transmission to zero for periods in countries such as Australia and New Zealand ^{10,11}. However, in these countries and elsewhere, as restrictions are relaxed, localized outbreaks have occurred ¹² that have required rapid, community-wide responses to again supress transmission. Importantly, these community constraints cause unprecedented civil disruption and come at enormous economic ^{13,14} and social costs ^{15,16}.

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

Since the evolution of dominant SARS-CoV-2 virus cannot be easily predicted ¹⁷, there remains a need to identify interventions that can be rapidly deployed should highly pathogenic strains emerge despite high levels of community immunization. Furthermore, preparations for the next pandemic must include strategies to limit the potential for infection and transmission on first contact with pathogenic respiratory viruses. One of the many therapeutic approaches investigated that appeared clinically useful early in the course of the pandemic was treatment with type 1 interferons (IFNs). Randomized, controlled studies suggest that IFNs offer clinical benefits in moderate ¹⁸ and severe disease ^{19,20} }, reduce the duration of viral shedding ²¹ and prevent infection in front-line hospital workers ²². Nonetheless, IFNs are not generally recommended for treatment of proven cases of Covid-19²³. Since IFNs are sentinel innate immune signalling molecules produced early after first contact with viral pathogens ²⁴⁻²⁶, we postulated that prophylactic IFN treatment might reduce susceptibility to infection of uninfected contacts of individuals with SARS-CoV-2 infection. Such post-exposure prophylaxis could provide non-specific, antiviral protection to curb episodic viral outbreaks ²⁷, help suppress community transmission, even in vaccinated populations, and therefore reduce the risk of emergence of dangerous mutations 4,28. We therefore undertook a cluster, randomized, controlled study of sub-cutaneous pegylated IFNβ-1α (Plegridy. Biogen Inc, Cambridge MA) administration to determine whether IFN β -1 α therapy given to index cases and household contacts can reduce transmission of SARS-CoV-2.

Methods

The Containing Coronavirus Disease-19 (ConCorD-19) trial was a prospective, cluster, randomized trial of subcutaneous (sc) administration of pegylated IFN β -1 α ("IFN β -1 α ") versus standard care (control) ²⁹. Each household of an index case was randomized to either the IFN β -1 α treatment or the standard care control arm. The study was approved by the Institutional Review Board of the Pontificia Universidad Católica de Chile and was registered with clinicaltrials.gov (NCT04552379). All participants provided written informed consent.

Trial population

Index cases were identified from databases of those with confirmed SARS-CoV-2 from COVID-19 clinics and emergency room visits in Santiago, Chile. Households were contacted by telephone to determine eligibility prior to enrolment. Individuals aged between 18 and 80 years who met inclusion and exclusion criteria were deemed as 'eligible' contacts with households only included if there was at least one eligible contact 29 . Enrolment and the first doses of IFN β -1 α - if in the intervention arm- had to be within 72 hours of the positive identification of SARS-CoV-2 by polymerase chain reaction (PCR) in index cases. A household was excluded if the index case had been in complete self-quarantine from other household members during the 48 hours prior to the diagnosis of SARS-CoV-2 infection 29 . Household characteristics were captured consistent with recommendations of the World Health Organization for assessing household transmission 30 . All participants implemented quarantine measures as mandated by local authorities and maintained a daily symptom diary which was collected and reviewed at each study visit by the study team (see online supplementary material). At any time during the trial, if a contact participant developed symptoms suggestive of COVID-19, a nasopharyngeal swab was taken by a member of a mobile health team for virus PCR testing in an

accredited SARS-CoV-2 diagnostic laboratory. Index cases were instructed to remain in isolation / quarantine for 11 days from onset of symptoms or, if asymptomatic, 11 days from the sample collection date that resulted in the COVID-19 diagnosis. Household contacts remained in isolation / quarantine for 11 days from date of the sample resulting in the diagnosis of the index case or of a newly diagnosed household member as per recommendations/rulings by local authorities.

Intervention

A mobile health team conducted home visits of all participant households on study days 1 (enrolment), 6, 11, 16 and 29. Index cases and eligible household contacts in the IFN β -1 α arm received three subcutaneous doses of IFN β -1 α (125 μ g/0.5ml x 0.5ml) on study days 1, 6 and 11. Ineligible contacts in the IFN β -1 α arm, as well as index cases and all household contacts in the SOC arm, received standard care. All participating households received information regarding hygiene, isolation, social distancing and wearing of facemasks as per public health advice at the time of enrolment. The IFN β -1 α injection was given by a trained member of a mobile health team and participants were recommended to take paracetamol (1000mg, 6 hourly) commencing at the same time as the IFN β -1 α for up to twenty-four hours, in order to mitigate predictable flu-like symptoms 31 .

Outcomes

The primary outcomes were (i) the proportion of index cases shedding SARS-CoV-2 at study day 11 in the IFN β -1 α compared to control arm and (ii) the proportion of household contacts shedding SARS-CoV-2 at day 11, in the IFN β -1 α compared to the control arm. Secondary and exploratory outcomes are listed in Supplementary Methods (Supplementary Table 1). Shedding was determined by the presence of SARS-CoV-2 by PCR in saliva collected on days 1, 6, 11, 16, 21, and 29 (see Supplementary

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

Methods). A SARS-CoV-2 PCR Ct value ≥40 was considered negative. Viral load was estimated from the Ct value using a standard algorithm (Supplementary Figure 1 Biospecimen collections The full schedule of biospecimen collection is provided in the supplementary methods (Supplementary Tables 2 and 3. All consenting, non-eligible household contacts also provided biospecimens according to the schedule collection for non-eligible household contacts. Adverse events These were classified in accordance with Good Clinical Practice ³², as non-serious or serious and as related or unrelated to the trial medication. Statistical considerations The study was designed at the start of the pandemic and there were few data to guide sample size calculations. We therefore planned both frequentist inference and Bayesian analyses based on assumptions from the available data. Households were randomized as individual clusters using a minimization technique (biased coin, P=0.7) in order to achieve balance between treatment arms, stratified by the number of people within the household ³³.

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

Sample size calculations assumed, α =0.025 and power 90%, a zero correlation between outcome measures and that the household-wise, type 1 error rate would be below 0.05 and power above 80%. The estimated average household size was 4, based on census data ³⁴. Primary outcomes: (i) SARS-CoV-2 shedding at study day 11 by index cases: Data from Wuhan suggested that the proportion of untreated index cases still shedding virus on study day 11 would be ~85% 35. Based on a two tailed Fisher's exact test, a sample size of 278 index cases (139 per arm) would have 90% power to detect a difference in the proportion of individuals shedding virus at study day 11, if the proportion in the IFN β -1 α arm was 65%. (ii) SARS-CoV-2 shedding at study day 11 by household contacts: We estimated the secondary infection rate (transmission within the household) where there is an untreated index case would be 28% ^{36,37}. Based on a stratified Cochran-Mantel-Haenszel test (two-tailed with intra-class correlation of 0.15), we estimated that a sample of 278 households (834 eligible household contacts) would have >90% power, at alpha 0.025, to detect an odds ratio of 0.5 for a reduction in transmission to a treated household contact. Based on these assumptions and estimates, we aimed to recruit 310 households (allowing for a 10% drop-out rate) and 930 eligible household contacts. We undertook 3 separate sets of analyses:

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

(A) Standard frequentist analyses based on the primary outcomes as stated in the protocol and described in the Statistical Analysis Plan (available online) and included intention to treat and per protocol approaches. (B) Exploratory frequentist analyses based on a modified dataset that accounted for biological implausibility and effects that might only be associated with active treatment (Figure 1 and Supplementary Table 1 for further explanations). Both frequentist analyses fitted linear mixed effects models using Ime4 ³⁸ (see Statistical Analysis Plan). (C) Exploratory Bayesian analyses using the same dataset as the exploratory frequentist analysis. Detailed methods are provided in the supplementary methods. Briefly, a generalized linear model with mixed effects was developed to estimate the probability of infection that is influenced by explanatory variables for each contact case. A stan glmer with binomial logit function in rstanarm R package was used ^{39,40}. The frequentist approach allowed us to estimate the effects of IFN β -1 α treatment on the risk of an individual becoming infected. Whereas the Bayesian analysis allowed us to determine whether the ring prophylaxis strategy using IFN β -1 α reduces the probability of transmission within the household of an infected index case. With regard to the filtered datasets, we observed, after locking the database, that a number of index cases had negative PCR results on the day of recruitment despite a previous positive diagnostic PCR test. In the exploratory analyses we therefore excluded households where the index case was unlikely to transmit virus because they were not shedding virus on days 1 and day 6 of the study. We

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

also excluded households where an eligible contact was already positive at recruitment and there were no other eligible negative cases in the household. We refer to the modified dataset as the population "at risk". We used the population at risk data to better understand the effects of IFN β -1 α treatment on transmission of virus within households. When undertaking these exploratory analyses, we considered effects during two time periods. Days 1-11 (Period 1) i.e., the treatment and isolation period when eligible contacts in the IFN β -1 α arm were likely to have elevated IFN levels based on the known pharmacokinetics of pegylated IFN β -1 α and days 12-29 (Period 2) the post-treatment and isolation period when biological effects of pegylated IFNβ-1 α were likely to be waning in treated individuals. Although samples were not obtained on days 12-15, we assumed that anyone who became infected during this period would likely still to have a positive PCR on day 16. Results Recruitment, participation, and completion data are shown in Figure 1. Participant demographic and basic household characteristics data are shown in Table 1. Between December 2020 and May 2021, three-hundred and forty-one households were enrolled and randomized, of which 137 (IFN β -1 α arm) and 151 (control arm) completed the study. Of the 1172 individuals randomized (IFN β -1 α arm = 607; Controls = 565), 53 individuals withdrew from the study, of which 15 were index cases; 35 (14 index cases) in the IFN β -1 α arm and 18 (1 index case) in the control arm. The reasons for withdrawal are summarized in the supplementary results (Supplementary Table 4). One index case withdrew before being allocated to a treatment arm.

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

Eighty-two households where the index case had a negative salivary PCR on Day 1 and 6, or where there were no eligible contacts who tested negative at recruitment, were excluded from the exploratory analyses. The remaining households were considered as the 'at risk' population. (Figure 1). (a) Primary analyses The outcomes for the intention to treat (ITT) and per protocol (PP) frequentist analyses were similar (Supplementary Results). There was no effect of IFN β -1 α treatment on duration of viral shedding in those treated (index cases or infected contacts) vs. controls (IC-INF: treatment OR = 0.979, 95%CI = 0.647 to 1.479); IC-ITT: treatment OR = 1.106, 95%CI = 0.657 to 1.863); IC-PP: treatment OR = 1.062, 95%CI = 0.622 to 1.810); Figure 2A). The observed reduction in transmission to household contacts associated with IFNbeta-1alpha by day 11 was not significant (EHC-ITT: treatment OR = 0.582, 95%CI = 0.271 to 1.247; HC: treatment OR = 0.577, 95%CI = 0.287 to 1.160; EHC-PP: treatment OR = 0.589, 95%CI = 0.272to 1.276; Figure 2B). Vaccination status did not affect these outcomes (Supplementary results). (b) Exploratory frequentist analysis of 'At Risk Population.' Of the at risk population, 33/164 (20%) in the IFN β -1 α arm became infected by day 29 of the study compared to 37/142 (26%) in the control arm (relative risk reduction in the IFN arm = 23%). The majority of the risk reduction occurred during the active treatment phase of the study (days 1 to 11). Treatment with IFN β -1 α was associated with a significant reduction in the odds of a positive saliva PCR for all household contacts compared to standard of care on Day 11 (p = 0.033; OR = 0.550, 95% CI 284 = 0.364 to 0.989). The treatment effect was not significant in the second period (days 12-29) was not 285 significant (OR = 0.968, 95% CI = 0.405 to 2.840) (Figure 2C) 286 (c) Exploratory Bayesian analysis: 287 Overall, there was a 95% probability of infection reduction within a household by IFN β -1 α treatment 288 289 and the credible interval for the reduction in transmission probability was in the order of 0.9 to 290 15.9%. During the active treatment period (days 1-11), there was a significant reduction in the odds of 291 transmission (Bayesian analysis (OR = 0.32, 95% Credible Interval = 0.11 to 0.83). In contrast, in 292 Period 2 (day 12-29), the 95% credible interval of Beta coefficients for the treatment group includes 293 zero and therefore treatment was not effective in this period (Figure 2C, Supplementary Figure 2). The effect of IFN β -1 α on transmission was independent of household size (Supplementary Figure 3) 294 295 296 To determine the effect of IFN β -1 α treatment on viral shedding in those who became infected, we 297 examined the viral load trajectories in household contacts who became PCR positive after day 1. We 298 did not observe any difference in viral load trajectory in those treated with IFN β -1 α compared to 299 controls (Figure 3A). Furthermore, there was no difference in peak viral load between treated 300 household contacts and controls who became infected (Figure 3B). 301 There were fifty-eight serious adverse events in index cases, twenty-seven hospitalizations due to 302 303 COVID-19 (25 in the treatment and 32 in the control arm) and was one death in the standard care arm 304 due to COVID-19 in an individual with significant co-morbidities. Twenty-six household contacts of index cases were hospitalized, 10 in the treatment arm and 16 in the control arm, the difference was 305 306 not statistically significant.

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

Discussion This prospective, household cluster randomized, ring prophylaxis trial demonstrated that IFNβ-1α may reduce household transmission of SARS-CoV-19. Pegylated IFN β -1 α is an FDA approved therapy for multiple sclerosis for which the pharmacokinetics and safety profile are well-characterized ⁴¹. The use of this formulation allowed us to predict the likely duration of activity of the three-dose regimen in order to cover the period of peak transmissibility of the virus. Using a mobile medical team to administer doses at home optimized adherence to therapy and allowed reasons for nonadherence and withdrawal to be accurately documented. Although the intention to treat and per protocol analyses failed to demonstrate a significant effect on primary outcomes, these analyses failed to account for index cases not shedding virus at randomization nor an absence of eligible contacts within a household. Using biologically plausible filters to define an at risk population provided a better understanding of the effects of IFN β -1 α than intention to treat or per protocol analyses. These exploratory analyses that took account of the likelihood that transmission could occur within a household provided a pragmatic assessment of the effects of IFN β -1 α therapy when given to household contacts as prophylaxis. The frequentist analysis of the at risk populations indicated that *individuals* treated with IFN were less likely to become infected than untreated individuals when exposed to virus with a relative risk reduction of 23%. The Bayesian analysis revealed that the probability was 95% that transmission was reduced in households randomized to IFN β -1 α therapy. This effect of IFN β -1 α on household transmission was only significant during the active treatment period. This highlights the physiological

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

importance of IFN β -1 α as a sentinel molecule ²⁴ and provides further evidence for post-exposure prophylaxis with IFN β -1 α as an antiviral strategy. To our knowledge, only one previous study assessed ring prophylaxis in COVID-19. Labhardt et al observed that a combination of lopinavir/ritonavir for 5 days as post-exposure prophylaxis was not effective at preventing infection in close contacts of index cases ⁴². The overall viral load trajectory we observed was very similar to that observed in a laboratory human challenge experiment using wild-type SARS-CoV-2 virus in healthy volunteers ⁴³. Treatment with IFNβ-1α had no effect on viral load trajectory; therefore, reduced viral shedding by infected individuals is unlikely to explain the protective effect on household transmission of IFN β -1 α treatment that we report. Given that treatment affected the probability of transmission only in the active treatment phase and appears unrelated to viral load, we speculate that the observed effects of IFNβ- 1α were direct through protection of the at risk, exposed individual rather than indirectly though effects on the index case. The ConCoRD-19 biorepository will allow further examination of the mechanisms of action of IFN β -1 α on resistance to infection. The study was undertaken prior to the emergence of the omicron strain of virus (Supplementary Figure 4). We calculated the sample size based upon known household transmission characteristics of the alpha strain which was the dominant strain of the virus early in the pandemic. Simple hygiene measures and quarantine of affected individuals within households could have contributed to lower rates of transmission than expected. Together with a smaller number of eligible household contacts than anticipated from census data, these factors may have reduced the power of the study for the

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

primary outcomes. The effect size observed in this study could be greater for variants with higher transmissibility such as the Omicron strains that are now the dominant worldwide. Nonetheless, the beneficial biological effect of IFN β -1 α treatment was evident in the at risk population and therefore, post-exposure or ring prophylaxis with IFN β -1 α warrants further investigation, particularly if additional virulent strains of SARS-CoV-2 emerge and for future pandemic virus preparedness. In summary, although intention to treat and per protocol analyses failed to demonstrate significant effects on primary outcomes, in a biologically defined, at risk population, the relative risk of infection for an individual treated with IFN β -1 α was reduced by 23.0%. Moreover, this is the first study to demonstrate ring prophylaxis with IFNβ-1α significantly reduces the probability of household transmission of SARS-CoV-2. The effect of IFN β -1 α was most obvious during the active phase of treatment. In situations where there is emergence of a highly pathogenic and transmissible mutant strain of SARS-CoV-2 despite high vaccination rates, or when there is a new viral pandemic, IFN β -1 α ring prophylaxis could be considered to reduce transmission in households or amongst critical workers and vulnerable communities. Ring prophylaxis with therapies that can interrupt transmission appears to be an effective strategy for highly contagious respiratory viruses. Funding. Biogen PTY Ltd. Supply of interferon as "Plegridy". The study was substantially funded by BHP Holdings Pty Ltd

Authorship

Authors Castro-Rodriguez; Fish; Kollmann; Iturriaga, Karpievitch and Shannon contributed equally to the conduct of the study and manuscript preparation as first authors. Authors Tebbutt, Diego García-Huidobro, Perret, Borzutsky and Stick contributed equally to the conduct of the study and manuscript preparation as senior authors.

Acknowledgements

Matthew Cooper (Telethon Kids Institute). Advice regarding protocol and establishment of randomization schedule. Alexia Foti (Telethon Kids Institute). Collating, reviewing, and editing documents. Zsuzsanna Hollander (PROOF Centre, Vancouver). Statistical advice and statistical analysis plan review. Nat Eiffler (Telethon Kids Institute). Project management, protocol development, data management. Jessica Meyer (University of Rochester). Assisting collation and formatting of tables and figures.

References

- 391 1. Alizon S, Haim-Boukobza S, Foulongne V, et al. Rapid spread of the SARS-CoV-2 Delta variant in
- 392 some French regions, June 2021. Euro Surveill 2021;26(28). DOI: 10.2807/1560-
- 393 7917.ES.2021.26.28.2100573.
- 394 2. Mishra S, Mindermann S, Sharma M, et al. Changing composition of SARS-CoV-2 lineages and rise
- of Delta variant in England. EClinicalMedicine 2021;39:101064. DOI: 10.1016/j.eclinm.2021.101064.
- 396 3. Twohig K, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for
- 397 SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study.
- 398 Lancet Infectious Diseases 2021. DOI: 10.1016/ S1473-3099(21)00475-8.
- 399 4. Winger A, Caspari T. The Spike of Concern-The Novel Variants of SARS-CoV-2. Viruses 2021;13(6).
- 400 DOI: 10.3390/v13061002.
- 401 5. Lyngse FP, Mortensen LH, Denwood MJ, et al. SARS-CoV-2 Omicron VOC Transmission in Danish
- 402 Households. medRxiv 2021.
- 403 6. Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and
- death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a
- 405 cohort study. Lancet 2022;399(10332):1303-1312. DOI: 10.1016/S0140-6736(22)00462-7.
- 406 7. Le Rutte E, Shattock A, Chitnis N, Kelly. SL, Penny M. Assessing impact of Omicron on SARS-CoV-2
- 407 dynamics and public health burden. medRXiv. Online server: Cold Spring Harbor Laboratory; 2021.
- 408 8. Centers for Disease Control and Prevention. Implementation of Mitigation Strategies for
- 409 Communities with Local COVID-19 Transmission. CDC. May 23 2021.
- 410 9. Milne GJ, Xie S, Poklepovich D, O'Halloran D, Yap M, Whyatt D. A modelling analysis of the
- 411 effectiveness of second wave COVID-19 response strategies in Australia. Sci Rep 2021;11(1):11958.
- 412 DOI: 10.1038/s41598-021-91418-6.

- 413 10. National Incident Room Surveillance Team. COVID-19 Australia: Epidemiology Report 38
- 414 Reporting period ending 28 March 2021. Commun Dis Intell (2018) 2021;45. DOI:
- 415 10.33321/cdi.2021.45.19.
- 416 11. Houvessou GM, Souza TP, Silveira MFD. Lockdown-type containment measures for COVID-19
- 417 prevention and control: a descriptive ecological study with data from South Africa, Germany, Brazil,
- 418 Spain, United States, Italy and New Zealand, February August 2020. Epidemiol Serv Saude
- 419 2021;30(1):e2020513. DOI: 10.1590/S1679-49742021000100025.
- 420 12. Conway SR, Lazarski CA, Field NE, et al. SARS-CoV-2-Specific T Cell Responses Are Stronger in
- 421 Children With Multisystem Inflammatory Syndrome Compared to Children With Uncomplicated SARS-
- 422 CoV-2 Infection. Front Immunol 2021;12:793197. DOI: 10.3389/fimmu.2021.793197.
- 423 13. Cutler DM, Summers LH. The COVID-19 Pandemic and the \$16 Trillion Virus. JAMA
- 424 2020;324(15):1495-1496. DOI: 10.1001/jama.2020.19759.
- 425 14. Verschuur J, Koks EE, Hall JW. Global economic impacts of COVID-19 lockdown measures stand
- out in high-frequency shipping data. PLoS One 2021;16(4):e0248818. DOI:
- 427 10.1371/journal.pone.0248818.
- 428 15. Chemen S, Gopalla YN. Lived experiences of older adults living in the community during the
- 429 COVID-19 lockdown The case of mauritius. J Aging Stud 2021;57:100932. DOI:
- 430 10.1016/j.jaging.2021.100932.
- 431 16. Mamun MA. Suicide and Suicidal Behaviors in the Context of COVID-19 Pandemic in Bangladesh:
- 432 A Systematic Review. Psychol Res Behav Manag 2021;14:695-704. DOI: 10.2147/PRBM.S315760.
- 433 17. Callaway E. Beyond Omicron: what's next for COVID's viral evolution. Nature 2021;600(7888):204-
- 434 207. DOI: 10.1038/d41586-021-03619-8.

- 435 18. Rahmani H, Davoudi-Monfared E, Nourian A, et al. Interferon β-1b in treatment of severe COVID-
- 436 19: A randomized clinical trial. Int Immunopharmacol 2020;88:106903. (In eng). DOI:
- 437 10.1016/j.intimp.2020.106903.
- 438 19. Alavi Darazam I, Shokouhi S, Pourhoseingholi MA, et al. Role of interferon therapy in severe
- 439 COVID-19: the COVIFERON randomized controlled trial. Sci Rep 2021;11(1):8059. (In eng). DOI:
- 440 10.1038/s41598-021-86859-y.
- 441 20. Davoudi-Monfared E, Rahmani H, Khalili H, et al. A Randomized Clinical Trial of the Efficacy and
- Safety of Interferon β-1a in Treatment of Severe COVID-19. Antimicrob Agents Chemother 2020;64(9)
- 443 (In eng). DOI: 10.1128/aac.01061-20.
- 444 21. Feld JJ, Kandel C, Biondi MJ, et al. Peginterferon lambda for the treatment of outpatients with
- 445 COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respir Med 2021;9(5):498-510. (In
- 446 eng). DOI: 10.1016/s2213-2600(20)30566-x.
- 447 22. Meng Z, Wang T, Chen L, et al. The Effect of Recombinant Human Interferon Alpha Nasal Drops to
- 448 Prevent COVID-19 Pneumonia for Medical Staff in an Epidemic Area. Curr Top Med Chem
- 449 2021;21(10):920-927. (In eng). DOI: 10.2174/1568026621666210429083050.
- 450 23. National Institutes of Health. Covid-19 Treatment Guidelines. In: Health NIH, ed.: United States
- 451 Goverment; 2021.
- 452 24. Lee AJ, Ashkar AA. The Dual Nature of Type I and Type II Interferons. Front Immunol 2018;9:2061.
- 453 DOI: 10.3389/fimmu.2018.02061.
- 454 25. Mazewski C, Perez RE, Fish EN, Platanias LC. Type I Interferon (IFN)-Regulated Activation of
- 455 Canonical and Non-Canonical Signaling Pathways. Front Immunol 2020;11:606456. DOI:
- 456 10.3389/fimmu.2020.606456.

- 457 26. Wang BX, Fish EN. Global virus outbreaks: Interferons as 1st responders. Semin Immunol
- 458 2019;43:101300. DOI: 10.1016/j.smim.2019.101300.
- 459 27. World Health Organization. Informal consultation on the role of therapeutics in COVID-19
- 460 prophylaxis and post-exposure prophylaxis. . Worl Health Organization.
- 461 28. Gentile I, Maraolo AE, Piscitelli P, Colao A. COVID-19: Time for Post-Exposure Prophylaxis? Int J
- 462 Environ Res Public Health 2020;17(11):3997. (In eng). DOI: 10.3390/ijerph17113997.
- 463 29. Iturriaga C, Eiffler N, Aniba R, et al. A cluster randomized trial of interferon ss-1a for the reduction
- of transmission of SARS-Cov-2: protocol for the Containing Coronavirus Disease 19 trial (ConCorD-19).
- 465 BMC Infect Dis 2021;21(1):814. DOI: 10.1186/s12879-021-06519-4.
- 466 30. World Health Organization. Household transmission investigation protocol for 2019-novel
- 467 coronavirus (COVID-19) infection. Epidemiological protocol. Geneva: World Health Organization,
- 468 February 28th 2020 2020. (WHO/2019-nCoV/HHtransmission/2020.4)
- 469 (https://www.who.int/publications/i/item/household-transmission-investigation-protocol-for-2019-
- 470 novel-coronavirus-(2019-ncov)-infection).
- 471 31. Reess J, Haas J, Gabriel K, Fuhlrott A, Fiola M. Both paracetamol and ibuprofen are equally
- 472 effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during
- 473 interferon beta-1a (AVONEX) therapy. Mult Scler 2002;8(1):15-8. DOI: 10.1191/1352458502ms771sr.
- 474 32. National Health and Medical Research Council. Guidance: Safety monitoring and reporting in
- 475 clinical trials involving therapeutic goods. Canberra: National Health and Medical Research Council;
- 476 2016.
- 477 33. Hofmeijer J, Anema PC, van der Tweel I. New algorithm for treatment allocation reduced
- selection bias and loss of power in small trials. J Clin Epidemiol 2008;61(2):119-24. DOI:
- 479 10.1016/j.jclinepi.2007.04.002.

- 480 34. National Institute of Statistics. Chile Population and Housing Census 2017. Santiago, Chile:
- National Institute of Statistics (Chile), 2021. (http://ghdx.healthdata.org/record/chile-population-and-
- 482 <u>housing-census-2017</u>).
- 483 35. World Health Organisation. Situation report 50. Coronavirus disease 2019 (COVID-19) 50. World
- Health Organisation, 2020. (https://www.who.int/emergencies/diseases/novel-coronavirus-
- 485 2019/situation-reports).
- 486 36. Yi B, Fen G, Cao D, et al. Epidemiological and clinical characteristics of 214 families with COVID-19
- 487 in Wuhan, China. Int J Infect Dis 2021. DOI: 10.1016/j.ijid.2021.02.021.
- 488 37. Curmei M, Ilyas A, Evans O, Steinhardt J. Constructing and adjusting estimates for household
- 489 transmission of SARS-CoV-2 from prior studies, widespread-testing and contact-tracing data. Int J
- 490 Epidemiol 2021;50(5):1444-1457. DOI: 10.1093/ije/dyab108.
- 491 38. Bates DM, M.; Bolker, B.; Walker, S. Fitting linear mixed-effects models using lme4. Journal of
- 492 Statistical Software 2015;67(1):1-48. DOI: doi:10.18637/jss.v067.i01.
- 493 39. Goodrich B, Gabry J, Ali I, S. B. Bayesian applied regression modeling via Stan. R package version
- 494 2.21.1. rstanarm 2020 (https://mc-stan.org/rstanarm.).
- 495 40. Brilleman SL, Crowther MJ, Moreno-Betancur M, Buros Novik J, Wolfe R. Joint longitudinal and
- 496 time-to-event models via Stan. StanCon 2018. 10-12 Jan 2018. Pacific Grove C, USA.
- 497 https://github.com/stan-dev/stancon_talks/. Joint longitudinal and time-to-event models via Stan. .
- 498 StanCon 2018. Pacific Grove, CA, USA2018.
- 499 41. Hu X, Seddighzadeh A, Stecher S, et al. Pharmacokinetics, pharmacodynamics, and safety of
- 500 peginterferon beta-1a in subjects with normal or impaired renal function. J Clin Pharmacol
- 501 2015;55(2):179-88. DOI: 10.1002/jcph.390.

42. Labhardt ND, Smit M, Petignat I, et al. Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial. EClinicalMedicine 2021;42:101188. DOI: 10.1016/j.eclinm.2021.101188.

43. Ben K, Alex M, Mariya K, et al. Nature Portfolio 2022. DOI: 10.21203/rs.3.rs-1121993/v1.

	Full study population		At risk population	
	SOC	IFN	soc	IFN
	(n = 565)	(n = 607)	(n = 246)	(n = 293)
Age (years)				
Mean (SD)	35.0 (19.4)	33.2 (18.7)	29.2 (21.0)	29.0 (20.0)
Sex	, ,	,	,	, ,
Female, n (%)	294 (52.0%)	323 (53.2%)	133 (54.1%)	171 (58.4%)
Male, n (%)	271 (48.0%)	284 (46.8%)	113 (45.9%)	122 (41.6%)
Household occupants	,	,	,	, ,
Mean (SD)	4.10 (1.31)	4.51 (2.02)	4.28 (1.30)	4.86 (2.24)
Fully vaccinated for SARS-CoV-2	•	, ,	, ,	
No, n (%)	380 (67.3%)	438 (72.2%)	167 (67.9%)	217 (74.1%)
Yes, n (%)	103 (20.3%)	169 (27.8%)	79 (32.1%)	76 (25.9%)
Cancer				
No, n (%)	559 (98.9%)	598 (98.5%)	245 (99.6%)	290 (99.0%)
Yes, n (%)	5 (0.9%)	9 (1.5%)	0 (0%)	3 (1.0%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
Diabetes				
No, n (%)	542 (95.9%)	583 (96.0%)	238 (96.7%)	285 (97.3%)
Yes, n (%)	22 (3.9%)	24 (4.0%)	7 (2.8%)	8 (2.7%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
Heart disease				
No, n (%)	533 (94.3%)	578 (95.2%)	236 (95.9%)	281 (95.9%)
Yes, n (%)	31 (5.5%)	29 (4.8%)	9 (3.7%)	12 (4.1%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
Asthma				
No, n (%)	524 (92.7%)	581 (95.7%)	230 (93.5%)	282 (96.2%)
Yes, n (%)	40 (7.1%)	26 (4.3%)	15 (6.1%)	11 (3.8%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
Chronic lung disease				
No, n (%)	564 (99.8%)	606 (99.8%)	245 (99.6%)	292 (99.7%)
Yes, n (%)	0 (0%)	1 (0.2%)	0 (0%)	1 (0.3%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
Chronic kidney disease				
No, n (%)	564 (99.8%)	604 (99.5%)	245 (99.6%)	292 (99.7%)
Yes, n (%)	0 (0%)	3 (0.5%)	0 (0%)	1 (0.3%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
Chronic neurological disease				
No, n (%)	562 (99.5%)	602 (99.2%)	245 (99.6%)	290 (99.0%)
Yes, n (%)	2 (0.4%)	5 (0.8%)	0 (0%)	3 (1.0%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
Smoker				
No, n (%)	502 (88.8%)	519 (85.5%)	227 (92.3%)	255 (87.0%)
Yes, n (%)	63 (11.2%)	88 (14.5%)	19 (7.7%)	38 (13.0%)
Missing, n (%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

Table 1: Full study population demographics at baseline, and at risk population demographics at baseline.




Figure 1: CONSORT diagram describing participant screening, enrolment, randomisation, and analysis.




Figure 2: Forrest plots describing primary and exploratory study outcomes. (A) odds ratios for index case populations in Primary Analysis 1 and associated sensitivity analyses, to compare the probability of being SARS-COV-2 negative vs positive on study day 11 in either treatment or standard of care arms. (B) odds ratios for household contact populations in Primary Analysis 2 and associated sensitivity analyses, to compare the probability of household contacts being SARS-CoV-2 negative vs positive on study day 11 in either treatment of standard of care arms. (C) odds ratios for the exploratory frequentist and Bayesian analysis, to determine if IFN is associated with a reduction in the number of positive COVID-19 tests in household contacts across study period 1 (days 1-11) and study period 2 (days 12-29). Treatment with IFN is associated with a significant reduction in the odds of a positive COVID-19 test for all household contacts compared to standard of care; frequentist analysis (p = 0.033; OR = 0.550, 95% CI = 0.364 to 0.989), Bayesian analysis (OR = 0.32, 95% CrI = 0.11 to 0.83). IC-INF = Infected case population (main analysis), IC-ITT = Index case – intention to treat population (sensitivity analysis 7.1.3.2), IC-PP = Index case – per protocol population (sensitivity analysis 7.1.3.3). EHC-ITT = Treatment-eligible household contact – intention to treat population (main analysis), HC = Household contact (eligible + non-eligible contacts) population (sensitivity analysis 7.2.3.2), EHC-PP = Treatment-eligible household contact = per protocol population (sensitivity analysis 7.2.3.3). * p < 0.05.

2

3

4

5

6

7

8

9

10

11

12

13

14

15




Figure 3: Log₁₀ viral load in study participants who test positive for COVID-19 after visit 1. (A) No significant difference in median viral load at each study visit between SOC and IFN arms. (B) No significant difference in peak viral load between SOC and IFN arms. SOC = standard of care arm, IFN = interferon arm, cp/mL = copies/mL. n = 57 (IFN) & n = 61 (SOC) participants per group.

Supplementary Materials

List of Study Investigators	3
Supplementary Methods	5
Real-time Quantitative Polymerase Chain Reaction (RT-qPCR) for SARS-CoV-2	5
Viral load calculation	5
Populations used for analyses	5
Bayesian statistical analysis	5
Bayesian model	6
Computation of difference in probability of infection in IFN vs SOC arms	6
Supplementary Results	7
Bayesian analysis of infection reduction	7
Supplementary Figures	8
Supplementary Figure 1: Standard curve for calculation of SARS-CoV-2 viral load	8
Supplementary Figure 2: Distribution of the difference in probability of infection between SOC and IFN arms by household size	
Supplementary Figure 3: Distribution of the difference in probability of infection between SOC and IFN arms.	
Supplementary Figure 4: COVID-19 variants detected in Santiago, Chile during study recruitment.	10
Supplementary Tables	11
Supplementary Table 1: Primary, secondary, and exploratory outcomes for the Containing Coronavirus Disease-19 clinical trial	12
Supplementary Table 2: Schedule of laboratory assessments for index cases and treatment eligible household contacts.	
Supplementary Table 3: Schedule of laboratory assessments for treatment ineligible household contacts.	14
Supplementary Table 4: Study withdrawal reasons by treatment arm.	15
Supplementary Table 5: Reasons for exclusion from study participation during screening and reasons for declined participation following invitation to participate in ConCorD-19	16
Supplementary Table 6: Study populations used for analysis, and reasons for exclusion from analysis.	17
Supplementary Table 7: Bayesian estimated beta coefficients and odds ratio for treatment with IFN, with average values and 95% credible intervals.	18
Supplementary Table 8: Difference in probability of infection in each study period irrespective of household size	
Supplementary Table 9: Difference in probability of infection in each study period, stratifying b household size.	
Supplementary Table 10: Number of contacts at each household size.	19
Supplementary References	
Supplementary Appendices	21

Jose A. Castro-Rodriguez

Department of Pediatric Pulmonology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Eleanor N. Fish

Department of Immunology, University of Toronto, Toronto, Canada Toronto General Hospital Research Institute, University Health Network, Toronto, Canada

Tobias Kollman

Telethon Kids Institute, University of Western Australia, Nedlands, Australia

Carolina Iturriaga

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Millennium Institute on Immunology and Immunotherapy, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Yuliya Karpievitch

Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia, Nedlands, Australia

School of Biomedical Sciences, University of Western Australia, Nedlands, Australia

Casey Shannon

Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, Canada Centre for Heart Lung Innovation, Providence Health, St Paul's Hospital, Vancouver, Canada

Virginia Chen

Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, Canada Centre for Heart Lung Innovation, Providence Health, St Paul's Hospital, Vancouver, Canada

Robert Balshaw

Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, Canada Centre for Heart Lung Innovation, Providence Health, St Paul's Hospital, Vancouver, Canada

Samuel T. Montgomery

Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia, Nedlands, Australia

School of Population Health, Curtin University, Bentley, Australia

Joseph Ho

Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia, Nedlands, Australia

Rym Ben Othman

Telethon Kids Institute, University of Western Australia, Nedlands, Australia

Radhouana Aniba

Telethon Kids Institute, University of Western Australia, Nedlands, Australia

Francisca Gidi-Yunge

School of Dentistry, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 24, 2022. The copyright holder for this preprint Lucyhid art nellertified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Telethon Kids Institute, University of Western Australia, Nedlands, Australia

Guillermo Pérez-Mateluna

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica De Chile, Santiago, Chile

Marcela Urzúa

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica De Chile, Santiago, Chile

Scott Tebbit

Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, Canada Centre for Heart Lung Innovation, Providence Health, St Paul's Hospital, Vancouver, Canada

Diego García-Huidobro

Department of Family Medicine, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Department of Family Medicine and Community Health, University of Minnesota, United States of America

Cecilia Perret

Department of Pediatric Infectious Diseases and Immunology , School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile

Arturo Borzutzky

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Millennium Institute on Immunology and Immunotherapy, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Stephen M. Stick

Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia, Nedlands, Australia

Perth Children's Hospital, Nedlands, Australia

Real-time Quantitative Polymerase Chain Reaction (RT-qPCR) for SARS-CoV-2

RNA extraction and RT-qPCR for SARS-CoV-2 detection was performed at the Infectiology and Molecular Virology Laboratory, Red Salud UC Christus, Santiago, Chile. RNA was extracted in parallel from saliva using the MagBind RNA extraction kit (#GN7101907, Maccura Biotechnology, Rockville, MD, USA) with the Auto-Pure 32A Nucleic Purification System (Maccura Biotechnology, Rockville, MD, USA), and using the RNA/DNA Purification Magnetic Bead Kit (#DA0630, DaAnGene, Guangzhou, CN) with the Smart32 Nucleic Acid Extraction Instrument (DaAnGene, Guangzhou, CN) according to manufacturer specifications. Real-time PCR amplification was performed using the LightMix Modular Wuhan CoV RdRP-gene kit (#53-0777-96, TIB MolBiol, Roche, Berlin, DE) targeting the RNA-dependent RNA polymerase (RdRP) gene, targeting SARS-COV-2, but not other SARS-like viruses (CoVNL63, CoV229E, HKE, OC43, MERS), with a positive control containing three separate diagnostic targets (E gene, N gene, RdRP). The reverse transcription and PCR processes occur in a single step in a real-time thermocycler (Lightcycler 480 II, Roche, Berlin, DE) with an analytical sensitivity of 10.6 copies per reaction. A cycle threshold (Ct) value of ≤ 37 was considered positive for SARS-CoV-2.

Viral load calculation

The viral load of SARS-CoV-2 detected in saliva was calculated using a standard curve. A commercial SARS-CoV-2 standard (#COV019, Exact Diagnostics, Fort Worth, TX, USA) at a concentration of 200,000 copies per mL (cp/mL) was extracted in triplicate using the RNA/DNA Purification Magnetic Bead Kit (#DA0630, DaAnGene, Guangzhou, CN) with the Smart32 Nucleic Acid Extraction Instrument (DaAnGene, Guangzhou, CN) according to manufacturer specifications. Following extraction, serial dilutions (1:10; 200,000cp/mL to 20cp/mL & 1:5; 200,000cp/mL to 64cp/mL) were used in triplicate for reverse transcription and RT-qPCR using the LightMix Modular Wuhan CoV RdRP-gene kit (#53-0777-96, TIB MolBiol, Roche, Berlin, DE) with the Lightcycler 480 II thermocycler (Roche, Berlin, DE), resulting in 9 replicates at each concentration. SARS-CoV-2 was detectable in all nine replicates at 200,000cp/mL, 40,000cp/mL, 20,000cp/mL, 8,000cp/mL, 2000cp/mL, and 1,600cp/mL, and a standard curve was generated using the mean Ct values for these concentrations (Supplementary Figure 1) to calculate SARS-CoV-2 viral load in samples of unknown titre, resulting in a lower limit of quantification of 1,600cp/mL.

Populations used for analyses

Participants were excluded for analysis as outlined in the statistical analysis plan, or as outlined in the exploratory analysis (Supplementary Appendix B). Total households and participants excluded and used in each population are described in Supplementary Table 6. Briefly, participants were excluded from the populations used in the primary analyses (IC-INF, IC-ITT, EHC-ITT, HC) if the study visit was not performed, or was performed outside the +/- 1 day window either side of the scheduled visit date (Statistical Analysis Plan 6.5). Participants who didn't complete the full course of the treatment were excluded from the Per Protocol populations used in the primary analyses (IC-PP, EHC-PP). In the exploratory analysis, whole households were excluded if the index case was SARS-CoV-2 negative via salivary PCR at study days 1 & 6, and if there were no SARS-CoV-2 negative eligible or ineligible contacts in the household at study day 1. Participants were then excluded from the exploratory analysis if they were SARS-CoV-2 positive via salivary PCR at study day 1. Participants were further excluded from the Bayesian analysis where household size was greater than 7, as these household sizes were unable to be modelled using Bayesian modelling.

Bayesian statistical analysis

Bayesian analysis was included in the original statistical analysis plan. The goal was to test the null hypothesis that treatment of household contacts with IFN β -1 α does not reduce the probability of transmission from an infected index case to household contacts. As outlined in the analysis plan, we used data to develop a data generating process governed by probabilities that a household contact of an index case would test positive to COVID-19, and non-informative prior was used.

A generalized linear model with mixed effects was developed to estimate the probability of infection for each contact. A stan_glmer with binomial logit function from the rstanarm package (1) was run using R (version 4.1.1) to obtain Beta coefficients for 4,000 simulated samples to estimate the probability of infection using the following model:

$$pcr \sim (1 \mid index) + vacc + viral + infected + eligible + sex + age + arm$$

where: pcr: binary COVID-19 test result, index: index case in the household – treated as a random effect, vacc: number of vaccinated household members, viral: log₁₀ viral load of the index case at the beginning of the period, infected: number of COVID-19 positive household members at the beginning of the period, eligible: whether the household contact was eligible for treatment, sex: sex of the household contact, age: age of the household contact, and arm: study arm (i.e. SOC/IFN) of the household were the fixed explanatory variables.

The features of the model were the same as the exploratory frequentist analysis, with the exception of adding the treatment period as a feature. Instead, the Bayesian analysis split the data into two periods (Period 1: study days 1–11, Period 2: study days 12–29) with analysis conducted separately. For period 2, COVID-19 positivity at day 11 was used to determine COVID-19 positive household members at the beginning of the period. The population used for analysis was the same as the "Atrisk" population used in the exploratory frequentist analysis (Supplementary Table 6), with the additional exclusion of participants in households with a size larger than 8.

Computation of difference in probability of infection in IFN vs SOC arms

In each simulation, we obtained a PCR outcome for each contact from the Bayesian model by applying the posterior_predict function in the rstanarm package to the observed data (1). We further computed the percent of infections in each treatment arm irrespective of household size (Supplementary Table 8) and for each household size (Supplementary Table 9). Furthermore, we computed the difference in probability of infection by subtracting the probability of infection in IFN arm from the probability of infection in SOC arm. As a results, we obtained 4000 differences (irrespective of household size) and 4000 differences for each household size

Significance of the treatment effect was determined by 95% credible interval (CrI) for the treatment Beta coefficient. If 0 was included in the CrI, the effect of treatment group was considered not significant. Average Beta coefficient and odds ratio for the effect of the IFN treatment as compared to SOC were computed in each study period. The average odds ratio of being infected with SARS-CoV-2 on IFN treatment vs. SOC was calculated by exponentiating the values of the average of the coefficients (Supplementary Table 7).


Bayesian analysis of infection reduction

Treatment with IFN had a significant effect in study period 1 as the 95% CrI for treatment coefficient did not include zero (Supplementary Table 7). However, IFN treatment did not have a significant effect in period 2 as the 95% CrI did include zero (Supplementary Table 7).


In study period 1, there was 95% probability of infection reduction between 0.9% to 15.9% due to the IFN treatment, with 8.5% median and mean infection reduction (Supplementary Table 8). In study period 2, there are 95% probability of infection reduction -6.7% to 4.8% due to the IFN treatment, with -9% of median and mean of infection reduction (Supplementary Table 8).

When we stratified the infection reduction by household size, only households' size 3 and 4 in period 1 had a 95% CrI without zero (Supplementary Table 9).


As the distribution of Bayesian estimated differences in probabilities of infection in study period 1 is centred to the right of 0 (Supplementary Figure 3A), IFN treatment had an effect on reducing SARS-CoV-2 transmission within households. However, as the distribution in study period 2 is centred around 0, it suggests IFN has no effect on SARS-CoV-2 transmission within households (Supplementary Figure 3B).



Supplementary Figure 1: Standard curve for calculation of SARS-CoV-2 viral load. Mean cycle threshold (Ct) values are plotted on the y-axis, and \log_{10} SARS-CoV-2 copies per mL (cp/mL) are plotted on the x-axis. Linear regression resulted in an R² value of 0.9972, to fit the equation y = -3.719x + 48.83.



Supplementary Figure 2: Distribution of the difference in probability of infection between SOC and IFN arms by household size. (A) Distribution in study period 1, and (B) Distribution in study period 2. Vertical dashed black line represents zero difference in probability of infection between SOC and IFN arms.



Supplementary Figure 3: Distribution of the difference in probability of infection between SOC and IFN arms. (A) Distribution in study period 1, and (B) Distribution in study period 2. Vertical black line represents zero difference in probability of infection between SOC and IFN arms.

Supplementary Figure 4: COVID-19 variants detected in Santiago, Chile during study recruitment. Data represents COVID-19 variants detected as a percentage of the total infections detected during this period.

Date (Week)

0%

202,427,44

2027/02/1/18

2021-2021-203

Supplementary Tables

Outcome & Outcome Measure
The proportion of index cases shedding SARS-CoV-2 at day 11 in the active arm compared to the standard of care arm
The proportion of household contacts shedding SARS-CoV-2 at day 11 in the active arm compared to the standard of care arm
Outcome & Outcome Measure
Duration (in days) of SARS-CoV-2 measured by PCR of samples taken on study days 1, 6, 11, 16, 21, and 29
Number of household contacts of participants in the IFN arm with positive upper airway PCR compared to that in the standard of care arm at day 1 & 11, and seroconversion (IgM) over the study period up to day 29
The proportion of infected cases in the active arm that are hospitalized of die due to COVID-19, as compared to the proportion in the standard of care arm
Incidence and severity of reported adverse events in the active arm compared to the standard of care arm
Biological samples and associated data will be stored for later access for ethically approved research relevant to the exploratory objective

Assess the impact of hostbiology on the viral transmission dynamics and response to IFN β -1 α in the household using unbiased systems biology

Integrate the demographic and clinical data with the biological host data to decipher potential interactions relevant to outcome of infection or exposure, as well as response to IFN β -1 α intervention

Integrate the demographic and clinical data with the biological host data to decipher potential interactions relevant to outcome of infection or exposure, as well as response to IFN β -1 α intervention

Estimate the secondary infection rate, serial interval, incubation period, duration of infectiousness, duration of detected shedding

<u>Individual level</u>: SARS-CoV-2 shedding as determined by PCR of upper respiratory samples analyzed as a function of time of exposure relative to the start of the intervention

<u>Household/Community level</u>: While each study arm will be assessed independently of each other as secondary objectives, we will assess the impact of any intervention on the entire household. When demographic and/or biological variables

Host immune response (anti SARS-CoV-2 antibodies, blood cytokines and chemokines), as well as blood and nasal mucosal host response (including but not limited to transcriptomics, metabolomics, proteomics, and epigenomics) to IFN β -1 α intervention, SARS-CoV-2 infection and their interaction

Supplementary Table 1: Primary, secondary, and exploratory outcomes for the Containing Coronavirus Disease-19 clinical trial

	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Extra Visit - Suspected COVID-19
Study Day	1	6	11	16	21	29	
	Dose 1	Dose 2	Dose 3				
Blood Samples							
Complete Blood count/ ESR	X					X	X
SARS-CoV-2 antibodies (IgGAM)	X					X	
Study sample 1	X	X	X			X	X
Study sample 2	X	X	X			X	X
Study sample 3	X	X	X			X	X
Airway samples							
Nasal brush	X						
Nasal lining fluid	X	X	X				
Airway Swab for COVID-19 diagnosis							X
Saliva Samples	_						
Saliva	X	X	X	X	X	X	X

Supplementary Table 2: Schedule of laboratory assessments for index cases and treatment eligible household contacts.

	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Extra Visit - Suspected COVID-19
Study Day	1	6	11	16	21	29	
	Dose 1	Dose 2	Dose 3				
Blood Samples							
Complete Blood count/ ESR							X
SARS-CoV-2 antibodies (IgGAM)						X	
Study sample 1						X	X
Study sample 2						X	X
Study sample 3						X	X
Airway samples							
Nasal brush	X						
Nasal lining fluid	X	X	X				
Airway Swab for COVID-19 diagnosis							X
Saliva Samples	_						
Saliva	X	X	X	X	X	X	X

Supplementary Table 3: Schedule of laboratory assessments for treatment ineligible household contacts.

Interferon arm										Standard of Care arm									
			Da	ys sin	ce er	rolm	ent						Da	ys sin	ce en	rolm	ent		
Withdrawal reason	3	4	5	10	11	14	15	21	28	Withdrawal reason	3	4	5	10	11	14	15	25	28
Family withdrew	0	0	5	0	0	2	0	0	0	Family withdrew	0	0	2	0	0	0	0	0	0
Interpersonal problems	0	0	3	0	0	0	0	0	0	Interpersonal problems	0	4	0	0	0	0	0	0	0
Lack of time	0	1	0	0	0	0	0	0	0	Lack of time	0	0	0	0	0	0	0	0	0
Other	0	0	0	0	0	0	0	0	0	Other	0	0	1	0	0	0	0	0	0
Parental decision	0	0	2	0	0	0	0	0	0	Parental decision	0	0	0	0	0	0	0	0	0
Poor health	0	0	1	0	0	1	0	0	0	Poor health	0	0	0	0	0	0	0	0	0
Sample collection problems	0	0	0	0	0	0	0	0	0	Sample collection problems	0	0	1	0	0	0	0	0	0
Side effects of drug	0	0	0	0	0	2	0	0	0	Side effects of drug	0	0	0	0	0	0	0	0	0
Uninterested	0	0	0	1	0	0	0	0	1	Uninterested	0	0	0	0	0	0	0	0	0
Unspecified	4	3	1	2	1	0	0	0	0	Unspecified	0	1	3	0	0	0	1	5	0
Work commitments	0	0	2	2	0	0	0	0	0	Work commitments	0	0	0	0	0	0	0	0	0

Supplementary Table 4: Study withdrawal reasons by treatment arm.

	nicción I /
All rights received. No rouse allowed without per Unable to be contacted	736
Days of symptoms > 5	777
Asymptomatic	306
Isolating from household contacts	219
Hospitalized	177
Confirmation of COVID-19 took longer than 72 hours	35
Deceased	2
Ineligible medical condition or treatment	67
Less than 18 years old	54
Pregnant, or plans on becoming pregnant	32
Previously infected with COVID-19	36
Greater than 80 years old	3
All eligible household contacts currently infected	514
Does not live with eligible household contact	412
Not the first infection in the household	392
Does not live in the Santiago metropolitan area	20
Reasons for not participating in ConCorD-19	
Index case declined	835
Eligible household contact declined	196
Total	4813

Supplementary Table 5: Reasons for exclusion from study participation during screening and reasons for declined participation following invitation to participate in ConCorD-19.

Analyses	outlined in SAP	Exc	Participants	s (n) included	ed for analyses		
Analysis	Population	Reason		Participants (n)	•	IFN	SOC
					IC	172	169
	Full study				EHC	177	165
	population				СР-НС	80	81
					IHC	178	150
Primary 1 -	IC-INF at day 11		No visit	22	IC	159	164
Main	IC-INF at day 11	Vis	it outside window	3	CP-HC	69	76
Primary 1 –	IC-ITT at day 11		No visit	12	IC	159	164
Sensitivity 1	IC-111 at day 11		it outside window	2	ic	139	104
Primary 1 –	IC-PP at day 11	No visit or	protocol deviation	26	IC	146	164
Sensitivity 2	IC-FF at day 11	Vis	1	IC	140	104	
Primary 2 – Main	EHC-ITT at day 11		20	ЕНС	166	156	
Primary 2 –					ЕНС	166	156
Sensitivity 1	HC at day 11		No visit	37	IHC	168	143
Primary 2 – Sensitivity 2	EHC-PP at day 11	No visit or j	protocol deviation	30	ЕНС	156	156
Explora	tory Analyses	Exc	clusions				
Analysis	Population	Reason	Households (n)	Participants (n)			
	Household	COVID-negative index case	33		ЕНС	164	142
Frequentist	contacts, COVID-	No household contacts at risk	49		EHC	104	142
riequentist	19 negative at	Household contact COVID		43	IHC	129	104
	study day 1	positive		73	inc	129	104
ъ .	Frequentist	TT 1 11 1 1 7	_	(1	EHC	152	139
Bayesian	population, household size ≤ 7	Household size > 7 5		61	IHC	113	104

Supplementary Table 6: Study populations used for analysis, and reasons for exclusion from analysis. IC: index case, EHC: Treatment eligible household contacts, CP-HC: COVID-19 positive household contacts, IHC: Treatment ineligible household contacts, IC-INF: IC & CP-HC, IC-ITT: Index case – intention to treat population, IC-PP: Index case – per protocol population, EHC-ITT: Treatment eligible household contacts – intention to treat population, HC: EHC and IHC, EHC-PP: Treatment eligible household contact – per protocol population.

Study period	Mean All rights rese	Standard Deviation	Lower limit (2.5%)	Upper limit (97.5%)
1	-1.17	0.52	-2.23	-0.19
2	0.27	0.55	-0.80	1.36

Odds ratio for tre	eatment with IFN		95% Credil	ble Intervals
Study period	Mean	Standard Deviation	Lower limit (2.5%)	Upper limit (97.5%)
1	0.32	1.68	0.11	0.83
2	1.31	1.73	0.45	3.90

Supplementary Table 7: Bayesian estimated beta coefficients and odds ratio for treatment with IFN, with average values and 95% credible intervals.

Study period	2.5%	25%	50%	Mean	75%	97.5%
1	0.009	0.059	0.085	0.085	0.110	0.159
2	-0.067	-0.028	-0.009	-0.009	0.010	0.048

Supplementary Table 8: Difference in probability of infection in each study period irrespective of household size. Data is the mean, median, and 95% CrI difference in probability of infection in each study period, computed as probability of infection in the SOC arm minus the probability of infection in the IFN arm.

Study period	Household size	2.5%	25%	50%	Mean	75%	97.5%
1	2	-0.143	0.000	0.286	0.053	0.143	0.286
1	3	0.000	0.092	0.276	0.139	0.184	0.276
1	4	0.003	0.087	0.249	0.128	0.170	0.249
1	5	-0.146	-0.046	0.158	0.005	0.058	0.158
1	6	-0.120	0.030	0.326	0.103	0.189	0.326
1	7	-0.231	-0.077	0.308	0.024	0.077	0.308
2	2	-0.118	-0.059	0.075	-0.008	0.000	0.075
2	3	-0.085	-0.021	0.090	0.001	0.028	0.090
2	4	-0.130	-0.068	0.059	-0.037	-0.006	0.059
2	5	-0.128	-0.052	0.103	-0.013	0.027	0.103
2	6	-0.129	-0.015	0.254	0.059	0.117	0.254
2	7	-0.154	0.000	0.154	0.016	0.077	0.154

Supplementary Table 9: Difference in probability of infection in each study period, stratifying by household size. Data is the mean, median, and 95% CrI difference in probability of infection in each study period, computed as probability of infection in the SOC arm minus the probability of infection in the IFN arm.

(Which we hold centified			nse to displaynte in graphet (in contractivity)
2	All rights reserved. No 1	euse allowed without permission 42	0
3	61	64	27
4	80	84	89
5	46	58	59
6	19	29	30
7	6	14	12

Supplementary Table 10: Number of contacts at each household size.

1. Goodrich B GJ, Ali I, Brilleman S. rstanarm: Bayesian applied regression modeling via Stan. R package version 2.21.3 ed2022.

Containing Coronavirus Disease 19 Trial (CONCORD-19): Statistical Analysis Report

Containing Coronavirus Disease 19 Trial (CONCORD-19)

Statistical Analysis Report

Design	Cluster randomised clinical trial
ClinicalTrials.gov identifier	NCT04552379
Protocol version	3.1
Statistical Analysis Plan version	2.5

Principal Investigators

Stephen Stick, MB BChir PhD MRCP FRACP
Perth Children's Hospital
15 Hospital Avenue, Nedlands WA 6009, Australia

Jose Antonio Castro-Rodriguez, MD PhD School of Medicine, Pontificia Universidad Católica de Chile Diagonal Paraguay 367, Santiago, Chile

Author

Virginia Chen, MA
Senior Data Scientist
PROOF Centre of Excellence
Vancouver, BC, Canada

Signatures

Statistician (Author)

Virginia Chen

Statistician (Reviewer)

Robert Balshaw

Statistician (Reviewer)

Casey P. Shannon

Table of Contents

- 1 Abbreviations
- 2 Introduction
 - 2.1 Document Purpose
 - 2.2 Trial Objectives
 - 2.3 Executive Summary
 - 2.4 Deviations from the SAP
 - 2.5 Other Details
- 3 Analysis Populations and Participant Disposition
 - 3.1 Full Analysis Population
 - 3.2 Index Case Intention-to-treat Population IC-ITT
 - 3.3 Index Case Per Protocol Population IC-PP
 - 3.4 Infected Case Population IC-INF
 - 3.5 Treatment-eligible Household Contact Intention-to-treat Population EHC-ITT
 - 3.6 Treatment-eligible Household Contact Per Protocol Population EHC-PP
 - 3.7 Household Contact Population HC
 - 3.8 Safety Population
- 4 Withdrawals
 - 4.1 Overall
 - 4.2 By Treatment Arm
- 5 Missing Data
- 6 Baseline Characteristics
 - 6.1 Full Analysis Population
 - 6.2 IC-ITT Population
 - 6.3 IC-INF Population
 - 6.4 EHC-ITT Population
 - 6.5 HC Population
- 7 Primary Analyses SAP 6.10

- 7.2 Primary Analysis 2 SAP 6.10.2
- 8 Secondary Analyses
 - 8.1 Secondary Analysis 1 SAP 6.10.3
 - 8.2 Secondary Analysis 2 SAP 6.10.4
 - 8.3 Secondary Analysis 3 SAP 6.10.5
 - 8.4 Secondary Analysis 4 SAP 6.10.6
- 9 Safety Analysis SAP 6.11
- 10 Additional Analyses SAP 6.12
 - 10.1 Dose-response and Recovery SAP 6.12.1
 - 10.2 Dose-response and Transmission SAP 6.12.2
 - 10.3 Viral Load SAP 6.12.3
- 11 Optional Analyses
 - 11.1 Bayesian Analysis
 - 11.2 Exploratory Two-period Generalized Mixed Effects Model

1 Abbreviations

AE	adverse event
AR	absolute risk
ARR	absolute risk reduction
GLM	generalized linear model
GLMM	generalized linear mixed model
HR	hazard ratio
IFN	interferon beta 1alpha (Biogen)
ITT	intention-to-treat
OR	odds ratio
PCR	polymerase chain reaction
RR	risk ratio
SAE	serious adverse event
SAP	statistical analysis plan
SARS-CoV-2	severe acute respiratory syndrome coronavirus 2
SD	standard deviation
soc	standard of care
SOP	standard operating procedure

2.1 Document Purpose

This document contains the results of the analyses described in the CONCORD-19 Statistical Analysis Plan (SAP). Descriptions of the analyses are omitted where the analysis proceeded as planned in the SAP. Any details or clarifying text are intended to be read in the context of the SAP.

2.2 Trial Objectives

2.2.1 Primary Objectives

- 1. To determine whether IFN therapy reduces the number of infected cases still shedding SARS-CoV-2 in saliva at day 11 following randomisation.
- To determine whether IFN therapy reduces the incidence of SARS CoV-2 transmission from index cases to treatment-eligible household contacts, as measured by any positive upper airway PCR in treatment-eligible household contacts at day 11 after randomisation

2.2.2 Secondary Objectives

- 1. To determine whether in index cases infected with SARS-CoV-2, IFN therapy compared with SOC reduces the duration of a saliva positive polymerase chain reaction (PCR) SARS-CoV-2 test over 28 days following randomisation.
- 2. To determine if IFN affects the incidence of saliva positive PCR SARS-CoV-2 tests or serological conversion by study day 29 in household contacts, compared with SOC.
- 3. To determine if IFN therapy, compared with SOC, reduces the proportion of infected cases that require hospital admission or die due to COVID-19.
- 4. To determine the safety of IFN treatment.

2.2.3 Exploratory Objectives

Exploratory objectives were not pursued at this stage.

2.3 Executive Summary

Primary objective 1

· Results do not suggest an effect

Primary objective 2

study day 11, but statistical significance was not achieved in any analysis

Secondary objective 1

· Results do not suggest an effect

Secondary objective 2

Results do not suggest an effect

Secondary objective 3

- Results suggest that IFN may increase duration of hospital stay, but statistical significance was not achieved in the main analysis
- IFN was statistically significant for reducing incidence of hospitalization in the sensitivity analyses
- IFN was statistically significant for increasing duration of hospital stay, in the sensitivity analyses

Secondary objective 4

• IFN was statistically significant for increasing incidence of treatment-related adverse events, but not for adverse events or serious adverse events in general

2.4 Deviations from the SAP

- 1. Two unplanned sensitivity analyses were added that take into account days between symptom onset and visit date for index cases. See "Adjusted for Days Between Symptom Onset and Visit Date" sections under "Sensitivity Analyses" for each Primary Objective.
- 2. Index cases occasionally had a negative PCR result on study day 1, despite testing positive prior to enrollment and testing positive at study day 6, 11, or 16. In these cases, their study day 1 viral load was imputed as 50% of their first nonnegative viral load recorded during the study. These imputed values were used only in sensitivity analyses and additional analyses. Additionally, a sensitivity analysis will be performed for primary analysis 1, by excluding index cases that tested negative at *both* study day 1 and 6.
- 3. An additional exploratory analysis into treatment effect during (D1-D11) and after (D12-29) discontinuation of treatment/household isolation is included (under Optional Analyses at the end of the report).

2.5 Other Details

For inclusion as a covariate, age was discretised by quartile. The breakdown is as follows:

SOC IFN

18 < Age <= 34	135	163
34 < Age <= 48	135	155
48 <= Age	156	127

3 Analysis Populations and Participant Disposition

3.1 Full Analysis Population

IFN							SOC						
	# Vis	sits co	onduc	ted at	study	day		# Visits conducted at study day					
	1	6	11	16	21	29		1	6	11	16	21	29
Index case	172	162	160	159	158	162	Index case	169	165	165	162	159	165
Treatment- eligible household contact	177	171	166	162	163	163	Treatment- eligible household contact	165	159	156	154	150	154
COVID- positive household contact	80	74	70	67	69	69	COVID- positive household contact	81	78	76	72	77	78
Treatment- ineligible household contact	178	173	168	169	169	167	Treatment- ineligible household contact	150	144	143	143	140	143

IFN

Reason for no visit

	Withdrawal	Household request	Research team decision	Other
Index case	37	3	0	19
Treatment-eligible household contact	45	1	0	14
COVID-positive household contact	44	0	0	7
Treatment-ineligible household contact	30	0	0	14

SOC

	Withdrawal	request	decision	Other
Index case	12	7	0	10
Treatment-eligible household contact	32	5	0	15
COVID-positive household contact	6	1	0	17
Treatment-ineligible household contact	24	5	0	8

3.2 Index Case - Intention-to-treat Population IC-ITT

IFN							SOC						
	# Vis	sits co	onduc	ted at	study	day		# Visits conducted at study d					
	1	6	11	16	21	29		1	6	11	16	21	29
Index case	172	162	160	159	158	162	Index case	169	165	165	162	159	165
Treatment- eligible household contact	0	0	0	0	0	0	Treatment- eligible household contact	0	0	0	0	0	0
COVID- positive household contact	0	0	0	0	0	0	COVID- positive household contact	0	0	0	0	0	0
Treatment- ineligible household contact	0	0	0	0	0	0	Treatment- ineligible household contact	0	0	0	0	0	0

3.3 Index Case - Per Protocol Population IC-PP

IFN							SOC						
	# Vis	sits co	onduc	ted at	study	/ day		# Vis	sits co	nduc	ted at	study	day
	1	6	11	16	21	29		1	6	11	16	21	29
Index case	146	146	146	145	143	145	Index case	169	165	165	162	159	165
Treatment- eligible household contact	0	0	0	0	0	0	Treatment- eligible household contact	0	0	0	0	0	0
COVID- positive	0	0	0	0	0	0	COVID- positive	0	0	0	0	0	0

Treatment- 0

3.4 Infected Case Population IC-INF

IFN							SOC						
	# Vis	sits co	onduc	ted at	study	day		# Visits conducted at study (
	1	6	11	16	21	29		1	6	11	16	21	29
Index case	172	162	160	159	158	162	Index case	169	165	165	162	159	165
Treatment- eligible household contact	0	0	0	0	0	0	Treatment- eligible household contact	0	0	0	0	0	0
COVID- positive household contact	80	74	70	67	69	69	COVID- positive household contact	81	78	76	72	77	78
Treatment- ineligible household contact	0	0	0	0	0	0	Treatment- ineligible household contact	0	0	0	0	0	0

3.5 Treatment-eligible Household Contact - Intention-to-treat Population EHC-ITT

	# \/:	oito oo	. m.d m	tod ot	o turds	. dov.		# \/:	ito oc	di.i.a	tod 04	o to o do	, dov
	# VI	sits cc	onduc	ieu ai	Study	uay		# VIS	sits cc	nduc	ieu ai	Study	uay
	1	6	11	16	21	29		1	6	11	16	21	29
Index case	0	0	0	0	0	0	Index case	0	0	0	0	0	0
Treatment- eligible household contact	177	171	166	162	163	163	Treatment- eligible household contact	165	159	156	154	150	154
COVID- positive household	0	0	0	0	0	0	COVID- positive household	0	0	0	0	0	0

Treatment- ineligible household	0	0	0	0	0	0	Treatment- ineligible household	0	0	0	0	0	0
contact							contact						

3.6 Treatment-eligible Household Contact - Per Protocol Population EHC-PP

	# Vis	sits co	onduc	ted at	study	day		# Visits conducted at study day					
	1	6	11	16	21	29		1	6	11	16	21	29
Index case	0	0	0	0	0	0	Index case	0	0	0	0	0	0
Treatment- eligible household contact	156	156	156	152	154	153	Treatment- eligible household contact	165	159	156	154	150	154
COVID- positive household contact	0	0	0	0	0	0	COVID- positive household contact	0	0	0	0	0	0
Treatment- ineligible household contact	0	0	0	0	0	0	Treatment- ineligible household contact	0	0	0	0	0	0

3.7 Household Contact Population HC

IFN							SOC						
# Visits conducted at study day					day		# Vis	sits co	nduc	ted at	study	day	
	1	6	11	16	21	29		1	6	11	16	21	29
Index case	0	0	0	0	0	0	Index case	0	0	0	0	0	0
Treatment- eligible household contact	177	171	166	162	163	163	Treatment- eligible household contact	165	159	156	154	150	154
COVID- positive household contact	0	0	0	0	0	0	COVID- positive household contact	0	0	0	0	0	0

ineligible ineligible household household contact contact

3.8 Safety Population

	# Visits conducted at study day				day		# Visits conducted at study					y day	
	1	6	11	16	21	29		1	6	11	16	21	29
Index case	172	162	160	159	158	162	Index case	169	165	165	162	159	165
Treatment- eligible household contact	177	171	166	162	163	163	Treatment- eligible household contact	165	159	156	154	150	154
COVID- positive household contact	80	74	70	67	69	69	COVID- positive household contact	81	78	76	72	77	78
Treatment- ineligible household contact	0	0	0	0	0	0	Treatment- ineligible household contact	0	0	0	0	0	(

4 Withdrawals

4.1 Overall

	Days since enrollment										
	3	4	5	10	11	14	15	21	28		
Family withdrew	0	0	7	0	0	2	0	0	0		
Interpersonal problems	0	4	3	0	0	0	0	0	0		
Lack of time	0	1	0	0	0	0	0	0	0		
Other	0	0	1	0	0	0	0	0	0		
Parental decision	0	0	2	0	0	0	0	0	0		
Poor health	0	0	1	0	0	1	0	0	0		
Sample collection problems	0	0	1	0	0	0	0	0	0		

Uninterested	0	0	0	1	0	0	0	0	1
Unspecified	4	4	4	2	1	0	1	5	0
Work	0	0	2	2	0	0	0	0	0

4.2 By Treatment Arm

IFN										SOC									
			Da	ys s	ince	enro	llme	nt					Da	ys si	ince	enro	llme	nt	
	3	4	5	10	11	14	15	21	28		3	4	5	10	11	14	15	21	28
Family withdrew	0	0	5	0	0	2	0	0	0	Family withdrew	0	0	2	0	0	0	0	0	0
Interpersonal problems	0	0	3	0	0	0	0	0	0	Interpersonal problems	0	4	0	0	0	0	0	0	0
Lack of time	0	1	0	0	0	0	0	0	0	Lack of time	0	0	0	0	0	0	0	0	0
Other	0	0	0	0	0	0	0	0	0	Other	0	0	1	0	0	0	0	0	0
Parental decision	0	0	2	0	0	0	0	0	0	Parental decision	0	0	0	0	0	0	0	0	0
Poor health	0	0	1	0	0	1	0	0	0	Poor health	0	0	0	0	0	0	0	0	0
Sample collection problems	0	0	0	0	0	0	0	0	0	Sample collection problems	0	0	1	0	0	0	0	0	0
Side effects of drug	0	0	0	0	0	2	0	0	0	Side effects of drug	0	0	0	0	0	0	0	0	0
Uninterested	0	0	0	1	0	0	0	0	1	Uninterested	0	0	0	0	0	0	0	0	0
Unspecified	4	3	1	2	1	0	0	0	0	Unspecified	0	1	3	0	0	0	1	5	0
Work	0	0	2	2	0	0	0	0	0	Work	0	0	0	0	0	0	0	0	0

All participants consented to the use of their collected data.

5 Missing Data

No imputation was performed.

6 Baseline Characteristics

	Overall (N=1172)
Age (years)	
Mean (SD)	34.1 (19.0)
Sex	
Female	617 (52.6%)
Male	555 (47.4%)
Household occupants	
Mean (SD)	4.31 (1.73)
Fully vaccinated for SARS-CoV-2	
No	818 (69.8%)
Yes	354 (30.2%)
Cancer	
No	1157 (98.7%)
Yes	14 (1.2%)
Missing	1 (0.1%)
Diabetes	
No	1125 (96.0%)
Yes	46 (3.9%)
Missing	1 (0.1%)
Heart disease	
No	1111 (94.8%)
Yes	60 (5.1%)
Missing	1 (0.1%)
Asthma	
No	1105 (94.3%)
Yes	66 (5.6%)
Missing	1 (0.1%)
Chronic lung disease	
No	1170 (99.8%)
Yes	1 (0.1%)
Missing	1 (0.1%)
Chronic kidney disease	
No	1168 (99.7%)
Yes	3 (0.3%)
Missing	1 (0.1%)
Chronic neurological disease	
No	1164 (99.3%)
Yes	7 (0.6%)
Missing	1 (0.1%)
Smoker	
No	1021 (87.1%)
Yes	151 (12.9%)

6.2 IC-ITT Population

SOC	IFN
(N=169)	(N=172)

Age (years)

Sex		
Female	82 (48.5%)	79 (45.9%)
Male	87 (51.5%)	93 (54.1%)
Household occupants		
Mean (SD)	3.74 (1.29)	3.90 (1.64)
Fully vaccinated for SARS-CoV-2		
No	106 (62.7%)	116 (67.4%)
Yes	63 (37.3%)	56 (32.6%)
Cancer		
No	166 (98.2%)	169 (98.3%)
Yes	3 (1.8%)	3 (1.7%)
Diabetes		
No	162 (95.9%)	163 (94.8%)
Yes	7 (4.1%)	9 (5.2%)
Heart disease		
No	158 (93.5%)	165 (95.9%)
Yes	11 (6.5%)	7 (4.1%)
Asthma		
No	157 (92.9%)	167 (97.1%)
Yes	12 (7.1%)	5 (2.9%)
Chronic lung disease		
No	169 (100%)	172 (100%)
Yes	0 (0%)	0 (0%)
Chronic kidney disease		
No	169 (100%)	172 (100%)
Yes	0 (0%)	0 (0%)
Chronic neurological disease		
No	169 (100%)	172 (100%)
Yes	0 (0%)	0 (0%)
Smoker		
No	147 (87.0%)	138 (80.2%)
Yes	22 (13.0%)	34 (19.8%)

6.3 IC-INF Population

	SOC (N=250)	IFN (N=252)
Age (years)		
Mean (SD)	42.2 (13.1)	40.5 (13.5)
Sex		
Female	129 (51.6%)	117 (46.4%)
Male	121 (48.4%)	135 (53.6%)
Household occupants		
Mean (SD)	3.83 (1.28)	3.98 (1.65)
Fully vaccinated for SARS-CoV-2		
No	158 (63.2%)	170 (67.5%)
Yes	92 (36.8%)	82 (32.5%)
Cancer		
No	246 (98.4%)	248 (98.4%)
Yes	4 (1.6%)	4 (1.6%)

No All rights reserved. No reuse	237 (94.8%)	237 (94.0%)
Yes	13 (5.2%)	15 (6.0%)
Heart disease		
No	232 (92.8%)	236 (93.7%)
Yes	18 (7.2%)	16 (6.3%)
Asthma		
No	230 (92.0%)	239 (94.8%)
Yes	20 (8.0%)	13 (5.2%)
Chronic lung disease		
No	250 (100%)	252 (100%)
Yes	0 (0%)	0 (0%)
Chronic kidney disease		
No	250 (100%)	252 (100%)
Yes	0 (0%)	0 (0%)
Chronic neurological disease		
No	249 (99.6%)	251 (99.6%)
Yes	1 (0.4%)	1 (0.4%)
Smoker		
No	215 (86.0%)	205 (81.3%)
Yes	35 (14.0%)	47 (18.7%)

6.4 EHC-ITT Population

	SOC (N=165)	IFN (N=177)
Age (years)	(14-100)	(1177)
Mean (SD)	41.6 (15.5)	38.0 (14.8)
Sex	()	33.3 (1.1.3)
Female	93 (56.4%)	107 (60.5%)
Male	72 (43.6%)	70 (39.5%)
Household occupants	,	,
Mean (SD)	4.00 (1.37)	4.54 (2.18)
Fully vaccinated for SARS-CoV-2		
No	80 (48.5%)	107 (60.5%)
Yes	85 (51.5%)	70 (39.5%)
Cancer		
No	165 (100%)	176 (99.4%)
Yes	0 (0%)	1 (0.6%)
Diabetes		
No	160 (97.0%)	169 (95.5%)
Yes	5 (3.0%)	8 (4.5%)
Heart disease		
No	160 (97.0%)	170 (96.0%)
Yes	5 (3.0%)	7 (4.0%)
Asthma		
No	157 (95.2%)	170 (96.0%)
Yes	8 (4.8%)	7 (4.0%)
Chronic lung disease		
No	165 (100%)	177 (100%)
Yes	0 (0%)	0 (0%)

No	165 (100%)	177 (100%)
Yes	0 (0%)	0 (0%)
Chronic neurological disease		
No	165 (100%)	175 (98.9%)
Yes	0 (0%)	2 (1.1%)
Smoker		
No	140 (84.8%)	145 (81.9%)
Yes	25 (15.2%)	32 (18.1%)

6.5 HC Population

	soc	IFN
	(N=315)	(N=355)
Age (years)		
Mean (SD)	29.3 (21.5)	28.0 (20.2)
Sex		
Female	165 (52.4%)	206 (58.0%)
Male	150 (47.6%)	149 (42.0%)
Household occupants		
Mean (SD)	4.31 (1.29)	4.89 (2.18)
Fully vaccinated for SARS-CoV-2		
No	222 (70.5%)	268 (75.5%)
Yes	93 (29.5%)	87 (24.5%)
Cancer		
No	313 (99.4%)	350 (98.6%)
Yes	1 (0.3%)	5 (1.4%)
Missing	1 (0.3%)	0 (0%)
Diabetes		
No	305 (96.8%)	346 (97.5%)
Yes	9 (2.9%)	9 (2.5%)
Missing	1 (0.3%)	0 (0%)
Heart disease		
No	301 (95.6%)	342 (96.3%)
Yes	13 (4.1%)	13 (3.7%)
Missing	1 (0.3%)	0 (0%)
Asthma		
No	294 (93.3%)	342 (96.3%)
Yes	20 (6.3%)	13 (3.7%)
Missing	1 (0.3%)	0 (0%)
Chronic lung disease		
No	314 (99.7%)	354 (99.7%)
Yes	0 (0%)	1 (0.3%)
Missing	1 (0.3%)	0 (0%)
Chronic kidney disease		
No	314 (99.7%)	352 (99.2%)
Yes	0 (0%)	3 (0.8%)
Missing	1 (0.3%)	0 (0%)
Chronic neurological disease		
No	313 (99.4%)	351 (98.9%)
Yes	1 (0.3%)	4 (1.1%)

No	287 (91.1%)	314 (88.5%)
Yes	28 (8.9%)	41 (11.5%)

7 Primary Analyses SAP 6.10

7.1 Primary Analysis 1 SAP 6.10.1

7.1.1 Main Analysis

This corresponds to SAP section 6.10.1 (Primary Analysis 1). Primary analysis 1 is carried out on participants from the IC-INF population, to compare the probability of index cases being SARS-CoV-2 negative vs positive per saliva PCR on the study day 11 saliva sample ("Not Shedding vs. Shedding") in either the treatment or soc arm of the study.

A total of 468 participants were used in this analysis.

Covariate	OR	95% CI
Intercept	0.199	[0.0284, 0.8756]
Age (bin 2)	1.519	[0.342, 10.616]
Age (bin 3)	1.129	[0.254, 7.891]
Age (bin 4)	1.504	[0.336, 10.552]
Male	2.138	[1.414, 3.263]
IFN treatment	0.979	[0.647, 1.479]

7.1.2 Supporting Analyses

7.1.2.1 Absolute Risk per Treatment Arm

A total of 468 participants were used in this analysis.

Treatment	N	AR	ARR	95% CI
SOC	237	0.287		
IFN	225	0.289	-0.00197	[-0.0846, 0.0806]

7.1.2.2 GLM with a Log Link

A total of 468 participants were used in this analysis.

This analysis did not converge.

7.1.3 Sensitivity Analyses

A total of 468 participants were used in this analysis.

Covariate	OR	95% CI
Intercept	0.202	[0.0289, 0.8893]
Age (bin 2)	1.654	[0.372, 11.570]
Age (bin 3)	1.352	[0.302, 9.494]
Age (bin 4)	1.884	[0.416, 13.333]
Male	2.119	[1.398, 3.241]
Vaccinated	0.604	[0.376, 0.956]
IFN treatment	0.963	[0.635, 1.459]

7.1.3.2 IC-ITT Population

This corresponds to SAP section 6.10.1 (sensitivity analysis B). Sentivity analysis B is carried out on participants from the IC-ITT population.

A total of 323 participants were used in this analysis.

Covariate	OR	95% CI
Intercept	0.115	[0.00566, 0.81281]
Age (bin 2)	1.961	[0.284, 39.261]
Age (bin 3)	1.272	[0.184, 25.425]
Age (bin 4)	2.453	[0.351, 49.321]
Male	2.224	[1.315, 3.833]
IFN treatment	1.106	[0.657, 1.863]

7.1.3.3 IC-PP Population

This corresponds to SAP section 6.10.1 (sensitivity analysis C). Sentivity analysis C is carried out on participants from the IC-PP population (excluding participants randomized to the IFN arm that received <3 doses; shown below).

A total of 310 participants were used in this analysis.

Covariate	OR	95% CI
Intercept	0.122	[0.006, 0.865]
Age (bin 2)	1.935	[0.280, 38.738]
Age (bin 3)	1.178	[0.169, 23.638]
Age (bin 4)	2.361	[0.337, 47.531]

IFN treatment 1.062 [0.622, 1.810]

7.1.4 Unplanned Analyses

7.1.4.1 Adjusted for Days between Symptom Onset and Visit

A total of 468 participants were used in this analysis.

This is an unplanned analysis. Days between symptom onset and visit date was included as a covariate.

Covariate	OR	95% CI
Intercept	0.294	[0.0246, 2.7823]
Age (bin 2)	1.519	[0.342, 10.629]
Age (bin 3)	1.138	[0.256, 7.959]
Age (bin 4)	1.539	[0.343, 10.807]
Male	2.114	[1.397, 3.229]
Days between symptom onset and visit date	0.973	[0.866, 1.090]
IFN treatment	0.987	[0.652, 1.494]

7.1.4.2 Excluding PCR Negative Index cases

A total of 427 participants were used in this analysis.

This is an unplanned analysis. Index cases that were PCR negative at both study day 1 and study day 6 were excluded.

Covariate	OR	95% CI
Intercept	0.208	[0.0298, 0.9172]
Age (bin 2)	1.771	[0.398, 12.384]
Age (bin 3)	1.151	[0.259, 8.044]
Age (bin 4)	1.573	[0.352, 11.037]
Male	2.071	[1.350, 3.209]
IFN treatment	0.938	[0.612, 1.436]

Below, I repeat the above, excluding *households* where the index case was PCR negative at both study day 1 and 6.

Covariate	OR	95% CI
Intercept	0.229	[0.0319, 1.0685]
Age (bin 2)	1.708	[0.364, 12.208]
Age (bin 3)	1.227	[0.260, 8.789]

Male	2.128	[1.383, 3.307]
Vaccinated	0.573	[0.349, 0.924]
IFN treatment	0.953	[0.619, 1.466]

7.2 Primary Analysis 2 SAP 6.10.2

7.2.1 Main Analysis

This corresponds to SAP section 6.10.2 (primary analysis 2). Primary analysis 2 is carried out on participants from the EHC-ITT population, to compare the probability of eligible household contacts being SARS-CoV-2 negative vs positive per saliva PCR on study day 11 ("Not Shedding") in either the treatment or soc arm of the study.

A total of 322 participants were used in this analysis.

Covariate	OR	95% CI
Intercept	0.505	[0.120, 2.129]
Age (bin 2)	0.749	[0.190, 2.948]
Age (bin 3)	0.276	[0.063, 1.214]
Age (bin 4)	0.195	[0.0411, 0.9215]
Male	0.755	[0.357, 1.598]
IFN treatment	0.582	[0.271, 1.247]

7.2.2 Supporting Analyses

7.2.2.1 Absolute Risk per Treatment Arm

A total of 322 participants were used in this analysis.

Treatment	N	AR	ARR	95% CI
SOC	156	0.154		
IFN	165	0.115	0.0387	[-0.036, 0.113]

7.2.2.2 GLMM with a Log Link

A total of 322 participants were used in this analysis.

This analysis did not converge.

7.2.3 Sensitivity Analyses

7.2.3.1 Adjusted for Risk Factors

Covariate	OR	95% CI
Intercept	0.00983	[0.000358, 0.269579]
Age (bin 2)	1.04996	[0.193, 5.718]
Age (bin 3)	0.37843	[0.055, 2.605]
Age (bin 4)	0.28665	[0.0384, 2.1416]
Male	0.84879	[0.353, 2.039]
Participated in any chores (study day 1-11)	1.24159	[0.252, 6.112]
Vaccinated	0.98930	[0.378, 2.586]
Seropositive at baseline	0.36852	[0.0885, 1.5344]
# Household occupants / # bedrooms	1.42006	[0.578, 3.491]
Household positivity rate	7.70447	[0.618, 95.992]
Log10(Baseline viral load of index case)	1.53349	[1.077, 2.183]
IFN treatment	0.49202	[0.202, 1.199]

7.2.3.2 HC Population

A total of 633 participants were used in this analysis.

Covariate	OR	95% CI
Intercept	0.194	[0.0679, 0.5543]
armNE	2.274	[0.917, 5.640]
Age (bin 2)	1.432	[0.499, 4.109]
Age (bin 3)	0.883	[0.292, 2.665]
Age (bin 4)	0.314	[0.105, 0.941]
Male	0.818	[0.464, 1.443]
IFN treatment	0.577	[0.287, 1.160]

7.2.3.3 EHC-PP Population

A total of 312 participants were used in this analysis.

Covariate	OR	95% CI
Intercept	0.574	[0.133, 2.487]
Age (bin 2)	0.670	[0.166, 2.705]
Age (bin 3)	0.257	[0.0572, 1.1555]
Age (bin 4)	0.174	[0.0359, 0.8411]

IFN treatment 0.589 [0.272, 1.276]

7.2.4 Unplanned Analyses

7.2.4.1 Adjusted for Days between Symptom Onset and Visit

A total of 322 participants were used in this analysis.

This is an unplanned analysis. Days between symptom onset *of the index case* and visit date was included as a covariate. The analysis did not converge.

8 Secondary Analyses

8.1 Secondary Analysis 1 SAP 6.10.3

This corresponds to SAP section 6.10.3 (secondary analysis 1). This analysis is carried out on the IC-INF population, using discrete time survival analysis to assess whether IFN treatment has an effect on the duration for which participants had SARS-CoV-2 positive saliva PCR.

Note that a higher hazard ratio is better, as it indicates a faster time to discharge from hospital.

8.1.1 Main Analysis

A total of 502 participants (totalling 2807 visits) were used in this analysis.

Covariate	HR	95% CI
Intercept	0.286	[0.179, 0.443]
Age (bin 2)	0.836	[0.540, 1.330]
Age (bin 3)	0.799	[0.517, 1.271]
Age (bin 4)	0.833	[0.537, 1.327]
Male	0.818	[0.728, 0.918]
Days since enrollment	1.110	[1.102, 1.118]
IFN treatment	1.083	[0.964, 1.217]

8.1.2 Sensitivity Analyses

8.1.2.1 IC-ITT Population

A total of 341 participants (totalling 1927 visits) were used in this analysis.

Covariate	HR	95% CI	

Age (bin 2)	0.830	[0.491, 1.460]
Age (bin 3)	0.800	[0.474, 1.405]
Age (bin 4)	0.686	[0.403, 1.213]
Male	0.888	[0.773, 1.021]
Days since enrollment	1.108	[1.099, 1.118]
IFN treatment	1.018	[0.886, 1.171]

8.1.2.2 IC-PP Population

A total of 315 participants (totalling 1830 visits) were used in this analysis.

Covariate	HR	95% CI
Intercept	0.341	[0.192, 0.580]
Age (bin 2)	0.839	[0.497, 1.471]
Age (bin 3)	0.816	[0.484, 1.431]
Age (bin 4)	0.692	[0.407, 1.223]
Male	0.909	[0.789, 1.048]
Days since enrollment	1.106	[1.096, 1.115]
IFN treatment	1.026	[0.890, 1.183]

8.2 Secondary Analysis 2 SAP 6.10.4

This corresponds to SAP section 6.10.4 (secondary analysis 2). This analysis is carried out on participants from the HC population.

8.2.1 Main Analysis

8.2.1.1 Incidence of SARS-CoV-2 Positive Saliva PCR on Study Day 1

The HC population consists of only household contacts that were PCR negative at visit 1, so this comparison is not applicable.

8.2.1.2 Incidence of SARS-CoV-2 Positive Saliva PCR on Study Day 11

A total of 633 participants were used in this analysis.

Incidence (SOC)	Incidence (IFN)	Cochran-Mantel-Haenszel p-value
0.208	0.173	0.329

8.2.1.3 Seroconversion at Study Day 29

A total of 594 participants were used in this analysis.

stratified by baseline immune status.

Incidence (SOC)	Incidence (IFN)	Cochran-Mantel-Haenszel p-value
0.537	0.415	0.0558

8.3 Secondary Analysis 3 SAP 6.10.5

This corresponds to SAP section 6.10.5 (secondary analysis 3). This analysis is carried out on participants from the IC-ITT population.

For this analysis, households with size greater than 8 were combined with the households of size 8, as there were not many of the former.

8.3.1 Main Analysis

8.3.1.1 Incidence of Hospitalization Due to COVID-19

A total of 299 participants were used in this analysis.

Outcome	Overall incidence in SOC	Overall incidence in IFN	Cochran-Mantel-Haenszel p-value
Hospitalized	0.101	0.0938	0.820

8.3.1.2 Incidence of Death Due to COVID-19

No deaths occurred in this analysis population.

8.3.1.3 Incidence of Hospitalization and/or Death Due to COVID-19

As there were no deaths in this analysis population, the results are the same as "Incidence of Hospitalization Due to COVID-19".

8.3.1.4 Duration of Hospital Stay Due to COVID-19

A total of 29 participants were used in this analysis.

As there were no deaths in this analysis population, a Cox proportional-hazards model was used instead. Note that a higher hazard ratio is better, in this case, as it indicates a faster discharge from the hospital.

Covariate	HR	95% CI
IFN	0.522	[0.237, 1.152]

8.3.2 Sensitivity Analyses

8.3.2.1 IC-INF Population

8.3.2.1.1 Incidence of Hospitalization Due to COVID-19

Outcome	Overall incidence in SOC	Overall incidence in IFN	Cochran-Mantel-Haenszel p-value
Hospitalized	0.109	0.0929	0.570

8.3.2.1.2 Incidence of Death Due to COVID-19

No deaths occurred in this analysis population.

8.3.2.1.3 Incidence of Hospitalization and/or Death Due to COVID-19

As there were no deaths in this analysis population, the results are the same as "Incidence of Hospitalization Due to COVID-19".

8.3.2.1.4 Duration of Hospital Stay Due to COVID-19

A total of 43 participants were used in this analysis.

As there were no deaths in this analysis population, a Cox proportional-hazards model was used instead. Note that a higher hazard ratio is better, in this case, as it indicates a faster discharge from the hospital.

Covariate	HR	95% CI
IFN	0.452	[0.233, 0.877]

Note discrepancy in number of hospitalizations reported (n = 44 vs. 43 reported) is caused by 1 participant where hospital duration could not be derived (CE 183 04 - no discharge date)

8.3.2.2 IC-PP Population

8.3.2.2.1 Incidence of Hospitalization Due to COVID-19

A total of 275 participants were used in this analysis.

Outcome	Overall incidence in SOC	Overall incidence in IFN	Cochran-Mantel-Haenszel p-value
Hospitalized	0.101	0.0294	0.0312

8.3.2.2.2 Incidence of Death Due to COVID-19

No deaths occurred in this analysis population.

8.3.2.2.3 Incidence of Hospitalization and/or Death Due to COVID-19

As there were no deaths in this analysis population, the results are the same as "Incidence of Hospitalization Due to COVID-19".

8.3.2.2.4 Duration of Hospital Stay Due to COVID-19

A total of 18 participants were used in this analysis.

As there were no deaths in this analysis population, a Cox proportional-hazards model was used instead. Note that a higher hazard ratio is better, in this case, as it indicates a faster discharge from the hospital.

FN 2.006 [0.601, 6.690]

8.4 Secondary Analysis 4 SAP 6.10.6

8.4.1 Main Analysis

A total of 844 participants (totalling 6784 visits) were used in this analysis.

8.4.1.1 Incidence of Adverse Events

Treatment	Rate of AE per participant	Incidence of any AE	Fisher's exact test
SOC	1.824	0.280	
IFN	2.117	0.235	0.156

8.4.1.2 Incidence of Adverse Events Related To Treatment

Treatment	Rate of related AE per participant	Incidence of any related AE	Fisher's exact test
SOC	0.00964	0.00964	
IFN	0.287	0.235	2.31e-27

8.4.1.3 Incidence of Serious Adverse Events

Treatment	Rate of SAE per participant	Incidence of any SAE	Fisher's exact test
SOC	0.0627	0.0578	
IFN	0.0559	0.0559	1.000

9 Safety Analysis SAP 6.11

See Secondary Analysis 4.

3 doses

10 Additional Analyses SAP 6.12

10.1 Dose-response and Recovery SAP 6.12.1

PCR negative at study day 11 PCR positive at study day 11 1 dose 3 1 2 doses 5 3

109

37

The p-value for the Fisher's exact test is 0.756.

10.2 Dose-response and Transmission SAP 6.12.2

PCR negative at study day 11 PCR positive at study day 11

1 dose	6	0
2 doses	3	1
3 doses	137	18

The p-value for the Fisher's exact test is 0.481.

10.3 Viral Load SAP 6.12.3

Growth rate is undefined (i.e. is missing) for participants whose peak viral load occurred on study day 1. Duration of infection is undefined. for participants whose last PCR result was positive. Decay is undefined for participants if their duration of infection is undefined.

	SOC (N=209)	IFN (N=209)
Peak viral load		
Mean (SD)	28,913,933 (196,793,258)	6,591,476 (33,775,900)
95% CI	[-364,672,583; 422,500,449]	[-60,960,324; 74,143,277]
Median [Q1; Q3]	220,461 [28,079; 1,741,659]	220,461 [32,374; 1,411,196]
Days to peak viral load		
Mean (SD)	1.87 (4.52)	1.40 (3.02)
95% CI	[-7.17; 10.92]	[-4.64; 7.44]
Median [Q1; Q3]	0.00 [0.00; 0.00]	0.00 [0.00; 0.00]
Growth rate		
Mean (SD)	262,111 (951,800)	431,891 (1,431,385)
95% CI	[-1,641,490; 2,165,711]	[-2,430,878; 3,294,661]
Median [Q1; Q3]	15,083 [2,003; 100,240]	4,747 [456; 40,673]
Missing	163 (78.0%)	163 (78.0%)
Duration of infection		
Mean (SD)	8.88 (6.89)	8.38 (6.29)
95% CI	[-4.90; 22.66]	[-4.19; 20.95]
Median [Q1; Q3]	6.00 [1.00; 16.00]	6.00 [6.00; 11.00]
Missing	31 (14.8%)	26 (12.4%)
Decay rate		
Mean (SD)	1,376,272 (4,574,811)	948,980 (4,379,841)
95% CI	[-7,773,350; 10,525,894]	[-7,810,702; 9,708,662]
Median [Q1; Q3]	58,102 [10,146; 294,797]	43,171 [11,186; 268,371]
Missing	33 (15.8%)	26 (12.4%)
Area under the curve		
Mean (SD)	75,272,876 (494,951,264)	19,688,768 (91,915,780)

Median [Q1; Q3]	698,934 [103,353; 6,628,988]	782,976 [127,664; 3,900,093]
Missing	2 (1.0%)	0 (0%)
Baseline viral load		
Mean (SD)	28,590,599 (196,824,913)	6,090,935 (33,614,342)
95% CI	[-365,059,226; 422,240,425]	[-61,137,749; 73,319,620]
Median [Q1; Q3]	144,737 [10,562; 1,270,280]	133,549 [18,435; 870,885]

Repeat including p-values for the comparisons between the groups (Wilcoxon Rank Sum Test).

	SOC (N=209)	IFN (N=209)	р
Peak viral load			
Mean (SD)	28,913,933 (196,793,258)	6,591,476 (33,775,900)	0.761
95% CI	[-364,672,583; 422,500,449]	[-60,960,324; 74,143,277]	
Median [Q1; Q3]	220,461 [28,079; 1,741,659]	220,461 [32,374; 1,411,196]	
Days to peak viral load			
Mean (SD)	1.87 (4.52)	1.40 (3.02)	0.855
95% CI	[-7.17; 10.92]	[-4.64; 7.44]	
Median [Q1; Q3]	0.00 [0.00; 0.00]	0.00 [0.00; 0.00]	
Growth rate			
Mean (SD)	262,111 (951,800)	431,891 (1,431,385)	0.416
95% CI	[-1,641,490; 2,165,711]	[-2,430,878; 3,294,661]	
Median [Q1; Q3]	15,083 [2,003; 100,240]	4,747 [456; 40,673]	
Duration of infection			
Mean (SD)	8.88 (6.89)	8.38 (6.29)	0.618
95% CI	[-4.90; 22.66]	[-4.19; 20.95]	
Median [Q1; Q3]	6.00 [1.00; 16.00]	6.00 [6.00; 11.00]	
Decay rate			
Mean (SD)	1,376,272 (4,574,811)	948,980 (4,379,841)	0.59
95% CI	[-7,773,350; 10,525,894]	[-7,810,702; 9,708,662]	
Median [Q1; Q3]	58,102 [10,146; 294,797]	43,171 [11,186; 268,371]	
Area under the curve			
Mean (SD)	75,272,876 (494,951,264)	19,688,768 (91,915,780)	0.856
95% CI	[-914,629,653; 1,065,175,405]	[-164,142,792; 203,520,328]	
Median [Q1; Q3]	698,934 [103,353; 6,628,988]	782,976 [127,664; 3,900,093]	
Baseline viral load			
Mean (SD)	28,590,599 (196,824,913)	6,090,935 (33,614,342)	0.883
95% CI	[-365,059,226; 422,240,425]	[-61,137,749; 73,319,620]	
Median [Q1; Q3]	144,737 [10,562; 1,270,280]	133,549 [18,435; 870,885]	

11 Optional Analyses

11.1 Bayesian Analysis

11.2 Exploratory Two-period Generalized Mixed Effects Model

This analysis is detailed in a separate document.

Containing Coronavirus Disease 19 Trial (CONCORD-19): Exploratory Analyses

Containing Coronavirus Disease 19 Trial (CONCORD-19)

Exploratory analysis, two-period glmer to explore treatment effect during and after treatment period in study-eligible and ineligible household contacts.

Casey P. Shannon (PROOF Centre of Excellence, University of British Columbia), true, Robert Balshaw (Centre for Healthcare Innovation, University of Manitoba)
2022-05-19

Introduction

Primary analysis 2 was carried out on participants from the EHC-ITT population, to compare the probability of eligible household contacts being SARS-CoV-2 negative vs positive per saliva PCR on study day 11 ("Not Shedding vs. Shedding") in either the treatment or soc arm of the study.

A planned sensitivity analysis adjusting for various risk factors had promising results (reduction of risk in the IFN arm), though this effect did not reach the pre-specified statistical significance threshold.

Here we revisit primary analysis 2, adopting a slightly modified approach incorporating treatment periods, and additionally considering non-eligible household contacts.

Rather than counting participants as positive based on their study day 11 sample SARS-CoV-2 saliva PCR, we count participants as PCR-positive according to whether they have had their first positive SARS-CoV-2 saliva PCR on any study day during period 1 (during treatment and isolation; D1-D11 inclusive) or period 2 (after treatment and isolation; D12-D29), or not at all.

Participants who test positive in period 1 are *not* counted in period two. Effectively, they are censored at their first positive saliva PCR as they are no longer at risk of becoming positive for the first time.

2. Inclusion of additional covariates

Household-level (hh_cov)

- Number of individuals in the household
- Number of vaccinated individuals in the household
- Viral load (log10 viral count) of the household index case on study day 1
- Number of individuals in the household with positive saliva PCR by the start of the period

These household level counts consider all household members (index cases and all treatment-eligible and treatment ineligible individuals in the household).

Individual-level (indv_cov)

- Participant eligibility (CE; eligible household contact/NE; non-eligible household contact)
- Participant age
- Participant sex

3. Models

- pcr ~ (1 | household) + hh_cov + indv_cov + period + trt
- pcr ~ (1 | household) + hh_cov + indv_cov + period + trt + period:trt

We test the hypothesis of an overall treatment effect by comparing model 2 to model 1 using the likelihood ratio test (LRT).

We test the hypothesis of an interaction between period and treatment (i.e., does treatment effect differ between the two periods) by comparing model 3 to model 2 using the likelihood ratio test (LRT).

P-values less than 0.05 are described as "significant", as is conventional, but the post-hoc nature of this analysis must be remembered.

4. Defining eligibility

Following internal discussion, we elected to exclude households from the analysis if:

- The index case subsequently tested negative (by saliva PCR) on both study day 1 AND study day 6 (negative index case)
- There were no negative household members (eligible OR non-eligible) at study day 1 (population at risk = 0)

Show code Show code

Table 1: Starting number of households per treatment arm.	
trt r	1
SOC 169	9
IFN 172	2

Table 2: Breakdown of corresponding participants.

SOC	169	81	165	150
IFN	172	80	177	178

Show code

Table 3: Number of households with a PCR positive index case.

trt n

SOC 149

IFN 159

Show code

Table 4: Breakdown of corresponding participants.

trt	IC	CEP	CE	NE
SOC	149	77	142	134
IFN	159	76	164	164

Show code

Table 5:
Households with a PCR positive index case and population at risk > 0 at start of period 1.

trt n

SOC 123

IFN 136

Analysis is carried out using this latter number of households.

Show code

Analysis

Table 6: Breakdown of corresponding participants.

trt	IC	CEP	CE	NE
SOC	123	42	142	125
IFN	136	49	164	151

While **eligible** contacts (CE) that were PCR(+) at the start of the study are tabulated separately above (as CEP), **ineligible** contacts (NE) that were PCR(+) at the start of the study were not explicitly identified in the same manner. Our analysis considers only the at risk population (at the start of each period), so we further exclude these participants below.

Show code

Table 7: Analysis population: Household contact population excluding those that were PCR(+) on study day 1.

trt	CE	NE
SOC	142	104
IFN	164	129

Incidence of infection

Finally, in order to provide some context, we report the incidence of infection in each study arm during the first period (on treatment; D1-11 inclusive), for eligible and non-eligible household contact populations.

Show code

Table 8: Incidence of infection in the eligible household contact population during treatment.

arm	trt	uninfected	infected	
CE	SOC	107	35	
CE	IFN	135	29	

during treatment.

arm	trt	uninfected	infected	
NE	SOC	79	25	
NE	IFN	103	26	

Model 2 vs. Model 1

This comparison answers the following question:

Is treatment with IFN associated with a reduction in the number of incident positive saliva PCR in household contacts, adjusting for individual risk factors (age, sex, and treatment eligibility) and household risk factors (num. individuals in household, num. vaccinated individuals, num. infected at start of period, viral load of index case), as well as treatment period (D1-11 vs. D11-29)?

Show code

term	npar	AIC	BIC	logLik	deviance	statistic	df	p.value
mod0	12.000	622.676	681.117	-299.338	598.676			
mod1	13.000	620.136	683.446	-297.068	594.136	4.541	1.000	0.033

coef	2.5 %	OR	97.5 %
(Intercept)	0.024	0.061	0.596
hh_size	0.803	1.002	1.177
hh_num_vacc	0.859	1.094	1.323
hh_viral_log10	1.022	1.346	1.614
hh_inf_start	0.896	1.212	1.529
armNE	0.398	0.928	2.021
sexM	0.365	0.490	0.810
age2	0.457	1.213	2.932
age3	0.417	1.065	2.512

period(11,30]	0.108	0.141	0.266
trtIFN	0.364	0.550	0.989

Conclusion

Treatment with IFN is associated with a significant reduction in the odds of a positive saliva PCR for all household contacts compared to standard of care (p = 0.033; OR = 0.550, 95% CI = 0.364 to 0.989).

Model 3 vs. Model 2

This comparison answers the following question:

Does the effect of treatment on the number of incident positive saliva PCR in household contacts change between study periods?

Show code

term	npar	AIC	BIC	logLik	deviance	statistic	df	p.value
mod0	12.000	618.151	676.592	-297.076	594.151			
mod1	13.000	619.077	682.387	-296.538	593.077	1.075	1.000	0.300

coef	2.5 %	OR	97.5 %
(Intercept)	0.031	0.060	0.520
hh_size	0.811	1.006	1.188
hh_num_vacc	0.866	1.093	1.332
hh_viral_log10	1.021	1.347	1.579
hh_inf_start	0.851	1.193	1.501
sexM	0.347	0.489	0.812
age2	0.738	1.299	2.124
age3	0.631	1.136	1.960
age4	0.297	0.498	1.023
period(11,30]	0.055	0.098	0.237

period(11,30]:trtIFN 0.710 1.917 4.703

Conclusion

Inconclusive: the effect of treatment does not appear to change between period 1 and period 2 (p = 0.300).

Show code

The point estimate for the treatment effect in the second period is OR = 0.968 (95% CI = 0.405 to 2.840) compared to OR = 0.550 (95% CI = 0.364 to 0.989) in the first period.

Summary Statement

In this *exploratory* analysis of the PCR results during periods 1 and 2 using the larger HC study population (eligible plus ineligible household contacts), and additionally considering treatment periods (during treatment, D1-D11; after treatment, D12-D29), IFN given to treatment eligible household contacts (and the COVID(+) index case) significantly reduced the odds of positive PCR results for all (non-positive at study day 1) household contacts (IFN likelihood ratio test p = 0.033; OR = 0.550, 95% CI = 0.364 to 0.989). Positive PCR tests are significantly less common in the second period (OR = 0.141, 95% CI = 0.108 to 0.266). The results for treatment and period summarized above were taken from the second model which excluded the treatment by period interaction as the interaction term was not significant (interaction LRT p = 0.300).




Figure 1: Treatment eligible (left) or ineligible (right) household contact population at risk over time stratified by randomization (red, treatment [IFN]; blue, standard of care).